Syringe for mixing two components and for retaining a vacuum in a storage condition

Information

  • Patent Grant
  • 10918796
  • Patent Number
    10,918,796
  • Date Filed
    Thursday, June 30, 2016
    8 years ago
  • Date Issued
    Tuesday, February 16, 2021
    3 years ago
Abstract
A syringe for mixing two substances which have been retained separately inside the syringe is described, for instance in a storage condition. The syringe is used for 1) retaining a dry composition in a vacuum, and 2) mixing the dry composition with an aqueous medium to form a flowable substance. One embodiment, a syringe for retaining and mixing first and second substances comprises a barrel comprising a sealable and/or closable distal outlet and a vacuum chamber for holding a first substance, a plunger incorporating a reservoir chamber for holding a second substance and configured to be axially displaced through a proximal end of the barrel, a membrane separating the vacuum chamber and the reservoir chamber, and a pointed member, such as one or more needles, for penetrating the membrane, wherein the syringe is configured such that the membrane and the pointed member are axially slidable in relation to each other.
Description

This application is the U.S. National Stage of International Application No. PCT/EP2016/065260, filed Jun. 30, 2016, which designates the U.S., published in English, and claims priority under 35 U.S.C. §§ 119 or 365(c) to EP Application No. 15175189.8, filed Jul. 3, 2015. The entire teachings of the above applications are incorporated herein by reference.


FIELD OF INVENTION

The present disclosure relates to a syringe for mixing two substances which have been retained separately inside the syringe, for instance in a storage condition. In particular the present disclosure relates to a syringe for 1) retaining a dry composition in a vacuum, and 2) mixing the dry composition with an aqueous medium to form a flowable substance.


BACKGROUND OF INVENTION

Mixing procedures and manipulations of different substances can be time consuming. Some types of medication are provided and stored in two separate chambers. Such medication may include a solid component and a liquid solvent and are known as two-part formulations. The solid component can be for example a powdered medicament. The substances can also include two liquid substances and/or two medicaments. Before the medicament is delivered, the components have to be mixed.


A syringe can generally be seen as a simple pump device consisting of a plunger in a tube, used to administer injections, insert intravenous drugs or apply compounds. There are a number of syringes capable of mixing and delivering two substances, including autoinjectors. In some of these syringes there are two chambers and a mechanism for mixing the substances either in one of the chambers or in a third chamber, before the mix is delivered, typically through a needle.


U.S. Pat. No. 4,048,999 shows a two-chamber syringe for medicinal purposes having one chamber for a liquid and one container for a solid or another liquid. The syringe has a stopper with an axial bore connecting the syringe to a vial and a second stopper sealing the axial bore and adapted to be ejected with the liquid in the syringe into the container by inward activation of the piston of the syringe.


It can be considered to be known in the art to include an inner needle in the syringe capable of transferring one component from one chamber to the other, thereby mixing the components. WO 2010/020800 A1 shows an autoinjector with mixing means, having a first and a second chamber for two different components. The autoinjector comprises both an injection needle and an internal transfer needle, wherein the transfer needle is capable of penetrating the stopper inside the autoinjector to establish fluid connection through the needle and mix the two components before they are injected.


The known syringes with several chambers and means for mixing several components are associated with a number of disadvantages. The mixing and injection are typically dependent on a manual movement lacking precise control or uses electrical power to control the mixing and injection. These designs are often overly complex and require precise finishing in order to work.


SUMMARY OF INVENTION

The present disclosure relates to a syringe for retaining and mixing first and second substances comprising a barrel comprising a sealable and/or closable distal outlet and a vacuum chamber for holding a first substance. The syringe preferably comprises a plunger, said plunger preferably incorporating a reservoir chamber for holding a second substance. The plunger may be configured to be axially displaced through a proximal end of the barrel. The syringe preferably comprises a membrane separating the vacuum chamber and the reservoir chamber. A pointed member, such as one or more needles, may be provided as part of the syringe suitable for penetrating the membrane. The syringe is preferably configured such that the membrane and the pointed member are axially slidable in relation to each other, preferably in correspondence with an axial displacement of the barrel relative to the plunger. I.e. the syringe is preferably configured such that an axial displacement of the plunger relative to the barrel corresponds to an axial displacement of the membrane and the pointed member relative to each other. For example if the membrane is attached to the plunger and the pointed member is attached to the barrel or vice versa.


The syringe may be configured such that an axial displacement of the plunger from a first position to a predefined second position in the barrel penetrates the membrane by the pointed member and establishes a fluid passageway between the reservoir chamber and the vacuum chamber. Preferably the vacuum in the vacuum chamber thereby aspirates the second substance into the vacuum chamber; the vacuum in the vacuum chamber thereby causing a transfer of the content of the reservoir chamber into the vacuum chamber, preferably without displacement of the plunger from said predefined second position. I.e. the reservoir chamber is thereby emptied or nearly emptied.


One advantage of the presently disclosed syringe is that a reservoir chamber is incorporated in the plunger for holding the second substance. Using the space inside the plunger to store one of the components makes the syringe more compact and lighter. The fact that the plunger is the movable part of the syringe (in relation to the barrel) can also render the design simple in that it is possible to mount the pointed member on the barrel, which is generally more stable than having the needle as a moving part.


Another advantage of the presently disclosed syringe is the vacuum chamber in the barrel for holding a first substance. If vacuum is created in the vacuum chamber, the vacuum may be utilized to move the plunger towards/inside the vacuum chamber and to aspirate the second substance from the reservoir chamber to the vacuum chamber. By first applying vacuum in the vacuum chamber and then letting the vacuum 1) pull the plunger, and 2) draw the content of the reservoir chamber into the vacuum chamber whereby the substances are mixed, the mixing process can be provided in a very controlled and automatic manner without involving manual force or manual movement of the plunger. If the parts of the plunger are produced in a process in which the parts always have the same size and shape, and the vacuum generation is applied in the same way, it can also be expected that the mixing will be performed in the same way every time.


The pointed member suitable for penetrating the membrane, wherein the syringe is configured such that the membrane and the pointed member are axially slidable in relation to each other, is another advantage of the presently disclosed syringe. If the needled is attached to the barrel and axially slidable in relation to the pointed member (which may be part of the plunger, constituting a separating barrier between the two chambers), the vacuum in the vacuum chamber may be used to move the plunger towards the vacuum chamber, the pointed member thereby penetrating the member and providing a fluid connection between the two chambers.


The combination of several of the abovementioned features can also be considered to further improve the design, which can be used with a range of additional mechanisms in order to make use of the invention. For example, the syringe may further comprise different kind of locking members to control the axial positions of the plunger inside the barrel. If vacuum is applied inside the vacuum chamber a mechanical locking mechanism can ensure that the plunger is not moved towards the vacuum chamber until the user removes the lock.


Furthermore, an axially slidable plug inside the plunger can be used to limit the reservoir chamber in the plunger. The syringe can be configured such that the plug slides distally inside the plunger when the substance in the reservoir chamber is transferred to the vacuum chamber. The plug can furthermore be used to plug the fluid connection between the two chambers when the substance of the reservoir of the first chamber has been transferred to the vacuum chamber. Preferably the plug is made of a material that can also be penetrated by the pointed member. Since, in one embodiment, the pointed member protrudes through the membrane after having penetrated the membrane, in a preferred embodiment the plug is made of a material that can also be penetrated by the pointed member, which allows that the plug is aspirated by the vacuum of the vacuum chamber to a position in which it abuts the distal end of the plunger or the member.


These and other aspects of the invention are set forth in the following detailed description if the invention.





DESCRIPTION OF DRAWINGS


FIG. 1A shows a cross-sectional illustration of one embodiment of the presently disclosed syringe with first and second locking elements, retaining vacuum in the vacuum chamber in a first configuration.



FIG. 1B shows the syringe of FIG. 1A where the first locking element has been removed and the aspiration force by the vacuum in the vacuum chamber has moved the plunger to a position in which a second substance in the reservoir chamber is transferred to the vacuum chamber through an axial separation section between the pointed member and the membrane. A second locking element prevents the plunger form moving further towards the vacuum chamber.



FIG. 1C shows the syringe of FIG. 1A-B where the vacuum in the vacuum chamber has emptied the reservoir chamber and moved the plug to abut the membrane. The second locking element still prevents the plunger from moving further towards the vacuum chamber.



FIG. 1D shows the syringe of FIG. 1A-C where the second locking element has been removed. The plug abuts the membrane. In this configuration the plunger can be pushed downwards to deliver the mixed content in the vacuum chamber through the outlet of the syringe.



FIG. 1E shows the syringe of FIG. 1A-D where the plunger and plug has been pushed downwards towards the vacuum chamber to empty the content of the vacuum chamber. The plug has been penetrated by the pointed member in this position.



FIG. 1F shows the syringe of FIG. 1A-E in the position where all the content of the vacuum chamber has been emptied by pushing the plunger to a final position.



FIG. 2 shows the proximal end of one embodiment of the presently disclosed syringe with a locking element engaging the plunger, a vacuum bypass channels, and a longitudinal protrusions adapted to match the vacuum bypass channel.



FIG. 3A shows an illustration of an exemplary plunger of the presently disclosed syringe.



FIG. 3B shows a cross-sectional illustration of the plunger in FIG. 3A.





The drawings are exemplary only and should not be construed as limiting the scope of the invention.


Definitions

“Ambient pressure” is herein used interchangeably with the term “atmospheric pressure”. It is the pressure in the surrounding area, i.e. the pressure in the location in which a process takes place.


A “reduced pressure” is a pressure below ambient pressure, i.e. a pressure below that of the pressure in the surrounding area in which a certain process operates.


“Vacuum” is herein defined as a region with a gaseous pressure less than the ambient pressure, i.e. the surrounding atmospheric pressure. At sea level on Earth the atmospheric pressure is approximately 1 bar, i.e. 1000 mbar at 25° C. The below table shows the approximate pressures in “low”, “medium” and “high” vacuum at sea level on earth in millibar (mbar).

















pressure (mbar)



















Atmospheric pressure
1000



Low vacuum
1000 to 100



Medium vacuum
100 to 0.001



High vacuum
<0.001










DETAILED DESCRIPTION OF THE INVENTION

As stated the present disclosure relates to a syringe for retaining and mixing first and second substances comprising a barrel comprising a sealable and/or closable distal outlet and a vacuum chamber for holding a first substance, a plunger incorporating a reservoir chamber for holding a second substance and configured to be axially displaced through a proximal end of the barrel, a membrane separating the vacuum chamber and the reservoir chamber, and a pointed member, such as one or more needles, for penetrating the membrane, wherein the syringe is configured such that the membrane and the pointed member are axially slidable in relation to each other.


By incorporating the plunger in the reservoir chamber, the syringe can be made more compact and lighter compared to a solution in which the barrel contains two chambers for separates substances. In one embodiment the reservoir chamber is completely contained in the plunger, and/or wherein the reservoir chamber is at least partly defined by outer walls of the plunger. Preferably the reservoir chamber is a closed volume within the walls of the plunger, possible having a lid or cap, alternatively having a plug inside the hollow plunger. In one embodiment the reservoir chamber is defined by a hollow portion of the plunger.


The syringe is preferably configured such that the membrane and the pointed member are axially slidable in relation to each other. The idea is that a membrane keeps the two substances in separate containers (i.e. reservoir chamber and vacuum chamber), initially without a fluid connection between the two. The fact that the membrane and the pointed member are axially slidable in relation to each other implies that the pointed member can penetrate and break the membrane when they meet if the pointed member is configured such that the pointed end of the pointed member points towards the membrane. Preferably, in such a design the pointed member is attached inside the barrel, preferably attached at the distal end of the barrel pointing towards the plunger and the membrane. This can be seen as a stable solution compared to having a needle that is moved inside the barrel.


Configurations and Locking Mechanism


The presently disclosed syringe may operate in one or several configurations. In one embodiment the syringe may be configured to retain vacuum in the vacuum chamber in a first configuration, said first configuration preferably being a storage condition of the syringe. In such a configuration the vacuum chamber is a closed container. Such a configuration may be useful not only to store the substance in the vacuum chamber, but can also be considered a “charged” state in that there is in an inherent energy in a vacuum chamber. When a vacuum chamber changes from a closed container to being in connection with another volume, an aspiration force arises. Therefore, if the syringe is configured to retain vacuum in the vacuum chamber in a first configuration, this force could then be released by connecting the vacuum chamber to the reservoir chamber.


In the first configuration, the syringe can be said to be in a state with inherent energy that could later be used to mix the substances of the two chambers, preferably without adding any external manual force to move the plunger.


In the first configuration, the membrane and pointed member are preferably axially separated inside the barrel. This ensures that the vacuum chamber remains a closed volume, retaining the vacuum, until the pointed member penetrates the membrane.


In one embodiment, the syringe is, in a second configuration, configured to provide a liquid communication between the vacuum chamber and the reservoir chamber.


Preferably, in this configuration the pointed member penetrates the membrane. The pointed member can be said to create the liquid communication between the two chambers. If vacuum has been applied to the vacuum chamber in the first configuration, the second configuration may then serve as a configuration in which the two substances are mixed in the vacuum chamber. This is achieved by the aspirating force from the vacuum chamber in combination with that fact that the two chambers now are in liquid communication. According to this description, the reservoir chamber and the vacuum chamber may therefore be fluidly disconnected in a first configuration, and fluidly connected in a second configuration.


The presently disclosure also relates to mechanical means for implementing the abovementioned configurations. In the first configuration, the membrane and pointed member are preferably axially separated inside the barrel while vacuum is retained in the vacuum chamber. As stated, in the vacuum state there is an inherent force that pulls the (typically axially movable) plunger towards the vacuum chamber. The displacement of the plunger can be prevented mechanically by a locking mechanism; therefore, in one embodiment, the presently disclosed syringe further comprises a removable locking member configured to engage and restrict the plunger from distal axial displacement inside the barrel. There are several ways of implementing such a locking mechanism. In one embodiment, the locking member is configured to engage the proximal part of the plunger extending from the proximal end of the barrel. An example of such a solution is shown in FIG. 1A. In this example, first locking element 9 abuts the plunger flange 11 and prevents the plunger from moving towards the vacuum chamber. In one embodiment, the first position is determined by the first and second locking elements engaging the plunger in combination, and wherein the second position is determined by only the second locking element engaging the plunger. In the mentioned example (FIGS. 1A and 1B), the first locking element is indirectly locked by the upper side of the barrel flange 12 (having a second locking element 10 in between the first locking element 9 and the barrel flange 12). The example shall not be seen as restricting the first locking element to this solution—other mechanical locking solutions of a removable locking member to restrict the plunger from distal axial displacement inside the barrel can be imagined. Therefore, in another embodiment, the locking member is configured to engage and restrict the plunger from distal axial displacement inside the barrel in two different axial positions of the plunger relative to the barrel.


In one embodiment of the presently disclosed syringe, the locking member comprises a first locking element and a second locking element, each of said locking elements configured to engage and restrict the plunger from distal axial displacement inside the barrel. The two locking elements may be placed such that the first and second locking elements are configured to engage the plunger in axial extension of each other. The second locking element can be used to lock the plunger in a second position in relation to the barrel (and possibly the pointed member). In this state the two substances can be mixed in the vacuum chamber, but the plunger is mechanically prevented from being further moved towards the distal end of the barrel to deliver the mixed content. Therefore, in one configuration of the presently disclosed syringe, the axial displacement of the plunger from a first position to a predefined second position penetrates the membrane by the pointed member and establishes a fluid passageway between the reservoir chamber and the vacuum chamber. Examples of the two configurations are shown in FIG. 1A and b respectively. In one embodiment the first configuration corresponds to a first axial position of the plunger (FIG. 1A, first and second locking element present) in the barrel and the second configuration corresponds to a second axial position of the plunger in the barrel (FIG. 1B, first locking element removed, second locking element present). As stated, and as can be seen in the example in FIGS. 1A and 1B, in one embodiment the syringe is configured such that the plunger is locked in a first configuration, and, in one embodiment the syringe is configured such that the plunger is locked in said second configuration.


In one embodiment, the presently disclosed syringe is configured such that the plunger is restricted from axial displacement in a distal direction in said first configuration, preferably by means of the removable first and second locking elements for engaging and locking the plunger in said first configuration. Distal direction in this context has the meaning that the plunger moves towards the distal end of the barrel. As stated this means, in a preferred embodiment, that the plunger is locked in the distal direction such that the pointed member does not penetrate the membrane and the substance cannot be mixed. When the plunger is unlocked (e.g. by removing the locking member), a vacuum in the vacuum chamber causes an axial displacement of the plunger from a first position to a second position. Similarly, in the second configuration, the plunger may be restricted from axial displacement in a distal direction, preferably by means of the removable second locking element adapted for engaging and locking the plunger in said second configuration.


A further aspect of the presently disclosed syringe relates to the pointed member comprising one or more liquid bypass channels configured to provide liquid communication between the reservoir chamber and the vacuum chamber upon penetration of the membrane, which is further explained below. In relation to the configuration and/or position of the parts of the syringe, the presently disclosed invention presents a solution of how to provide a liquid path between the two chambers upon penetration of the membrane by the pointed member. The inventors have realized that by locking the membrane (preferably located at the distal end of the plunger) in an axial direction in relation to the pointed member, the bypass channel can be positioned such that it allows substance to flow from the reservoir chamber to the vacuum chamber. Therefore, in one embodiment, the syringe is configured such that in the second configuration and/or second position the at least one of said one or more bypass channels are axially aligned with the membrane. An example of such an alignment can be seen in FIG. 1B, in which the bypass channel 15 (small recess or groove in the pointed member) is axially aligned with the membrane 7, such that substance can flow from the reservoir chamber 6 to the vacuum chamber 4.


Membrane and Pointed Member


As stated, the presently disclosed syringe has a membrane separating the vacuum chamber and the reservoir chamber, and a pointed member, such as one or more needles, for penetrating the membrane. In a preferred embodiment, the membrane separates a proximal end of the vacuum chamber and a distal end of the reservoir chamber. In one embodiment, the membrane is attached to and/or forms the distal end of the plunger. If the plunger has a hollow body or hollow portion, this means that the membrane constitutes a portion or the whole of the bottom/distal side of the plunger. An example of such an implementation is shown in FIGS. 1A-F. A plunger of a syringe may be cylindrical having a rounded end (like a test tube) or a substantially flat distal end, wherein the distal end is substantially circular in the case of a cylindrical shape of the plunger. Therefore, in one embodiment, a part of the distal end may be replaced by a material that can be penetrated by the pointed member. Preferably, the plunger is made of a hard material, such as plastic, and the membrane is made of a soft/softer material, e.g. rubber like material. The idea of this embodiment is that the pointed member should penetrate the membrane upon a distal displacement of the plunger inside the barrel. In this regard the plunger (including the membrane) can be considered to be the moving part of the design, whereas the barrel can be considered to be the fixed part. The syringe preferably comprises a sealed engagement between the plunger and barrel, e.g. in the form of a rubber seal in a distal end of the plunger, also helping to retain a vacuum in the vacuum chamber in the first configuration of the presently disclosed syringe. As illustrated in FIG. 3 the membrane 7 can be attached to the distal end of the plunger 5 via annular protrusion 19. The membrane 7 comprises the penetratable membrane barrier 7′ and a sealing flange 20 providing a sealed engagement with the barrel 2.


In one embodiment the pointed member is attached inside the barrel, preferably attached at the distal end of the barrel. In this configuration, the pointed member and the membrane can move in relation to each other. The pointed member preferably extends axially inside the barrel, i.e. in the longitudinal direction of the barrel. In the example in FIG. 1A it can be seen how the pointed member is attached to the distal end of the barrel, extending axially inside the barrel from the distal end of the barrel and pointing towards the proximal end of the barrel.


As stated, the idea of having a pointed member that can penetrate the membrane between the reservoir chamber and the vacuum chamber is to provide a bypass channel that makes use of the vacuum of the vacuum chamber to aspirate substance from the reservoir chamber to mix with the substance of the vacuum chamber. Therefore, in one embodiment of the presently disclosed syringe, the pointed member comprises one or more liquid bypass channels configured to provide liquid communication between the reservoir chamber and the vacuum chamber upon penetration of the membrane. The liquid bypass channel could be in the form of a hollow needle. The liquid bypass channel could also make use of the locking mechanism and second configuration described above. The inventors have realized that if the second configuration corresponds to a second locked axial position of the plunger in the barrel, this known position can be used to design the liquid bypass channel. As can be seen in e.g. FIG. 1B, a locking mechanism ensures that the pointed member and the member have a predefined locked position in relation to each other. In this configuration the liquid communication between the reservoir chamber and the vacuum chamber is provided for predefined axial position of the plunger, preferably only for said predefined axial position. In FIG. 1B the bypass channel 15 is axially aligned with the membrane, thereby providing a liquid path between the reservoir chamber and the vacuum chamber through small recesses of the pointed member. Since the pointed member is radially thinner in level with the recesses, and a radically thicker part has penetrated the membrane to reach this locked position, the membrane can be considered to have an opening that is larger than the cross-section of the pointed member in level with the recesses, thereby providing a liquid bypass channel between the two chambers. A further advantage of the liquid bypass channel formed as a recess as exemplified in the drawings is that the liquid (and fluid) communication is only established in one predefined axial position of the plunger relative to the barrel. If the plunger is moved further distally inside the plunger, as illustrated in FIGS. 1E and 1F, the liquid (and fluid) communication between the reservoir chamber and the vacuum chamber is closed again if the membrane and the pointed member are configured to provide a fluid and/or liquid tight engagement when the membrane is penetrated by the pointed member but the membrane is separated from the liquid bypass channel. Hence, the presently disclosed syringe may be configured such that the membrane and the pointed member form a sealed engagement when the pointed member penetrates the membrane and the membrane is axially separated from said one or more liquid bypass channels.


“Pointed” in relation to the presently disclosed syringe should be construed broadly in the sense that it could be any pointed structure capable of penetrating or breaking the membrane, typically a structure having a sharp top, such as a needle. In one embodiment, the pointed member is formed as an elongated pointed element wherein one end of the pointed element, preferably the proximal end, is pointed, such as pointed like a needle. Proximal is defined in the same way as proximal of the plunger and the barrel, i.e. opposite to distal i.e. opposite to the outlet and outer needle of the syringe.


In one embodiment, the liquid bypass channels are located adjacent to the proximal end of the pointed member. This has the advantage that the rest of the pointed member (i.e. below the bypass channel towards the distal part of the vacuum chamber) can be maintained as a mixing container in the locked second position. In one embodiment, one or more liquid bypass channels are formed as one or more recesses, such as one or more radial recesses, of the pointed member located distal from the proximal part of the pointed element. The liquid bypass channels, formed as one or more recesses, may be placed less than 1 mm, or less than 2 mm, or less than 3 mm, or less than 4 mm, or less than 5 mm, or less than 6 mm, or less than 7 mm, or less than 8 mm, or less than 10 mm, or less than 12 mm, or less than 14 mm, or less than 16 mm, or less than 18 mm, or less than 20 mm from the proximal end of the pointed member.


Plug


In a further embodiment of the presently disclosed invention, the syringe further comprises an axially slidable plug inside the plunger, preferably sealably engaged with the inside of the plunger which may be hollow, such that the reservoir chamber can be defined (proximally) by the plug inside the hollow plunger. This means that the plug can constitute a proximate sidewall of the closed reservoir chamber—the reservoir chamber is preferably located in the distal end of the plunger and defined distally by the distal end of the plunger and proximally by the axially slidable plug. Preferably, the plug is axially slidable inside the plunger, and can be used to plug the fluid connection between the two chambers when the substance of the reservoir of the first chamber has been transferred to the vacuum chamber. Since the plug defines a proximate sidewall of the reservoir, the reservoir chamber can alternatively be seen as an empty or nearly empty volume when the plug has been aspirated to a distal position abutting the distal end of the plunger or the member. In this position the content of the reservoir chamber has been transferred to the vacuum chamber.


Since, in one embodiment, the pointed member protrudes through the membrane after having penetrated the membrane, in a preferred embodiment the plug is made of a material that can also be penetrated by the pointed member, which allows that the plug is aspirated by the vacuum of the vacuum chamber to a position in which it abuts the distal end of the plunger or the member.


In a preferred embodiment, the plug is placed inside the plunger, and in an even more preferred embodiment, the plug is completely contained within the hollow body of the plunger. If the plunger is cylindrical, i.e. having a substantially circular cross-section, the plug should also have a substantially similar cross-section in order to seal the reservoir chamber. In this kind of embodiment, the plug can be considered to be recessed within the hollow body of the plunger. Preferably, the axially slidable plug is suitable for being penetrated by the pointed member, preferably only by means of the aspiration force exerted by the vacuum in the vacuum chamber.


When the discharge/transfer of substance from the reservoir chamber to the vacuum chamber takes place, the plug is typically aspirated towards the distal end of the plunger. Therefore, in one configuration of the presently disclosed syringe, upon penetration of the membrane and provision of a liquid communication between the vacuum chamber and the reservoir chamber, a vacuum in the vacuum chamber draws liquid contained in the reservoir chamber into the vacuum chamber along with an axial distal displacement of the plug within the hollow body. Furthermore, in such a configuration, the plug is configured to be axially displaced distally within the hollow body of the plunger during discharge/flushing of the second substance in the reservoir chamber into the vacuum chamber.


Other embodiments of the plug are also possible. The plug can be made of an expandable or elastic material, or, alternatively, the plug can be formed as a second small plunger adapted to fit and be recessed within the hollow plunger. Besides the advantage that plungers have proved to work for the purpose of keeping an inner volume sealed and push the volume to deliver it through a needle or other liquid connection, it opens the possibility for having a third chamber (i.e. a second separate reservoir) in the second plunger and mix more than two substances.


Vacuum Bypass Channel


As stated, the presently disclosed invention relates to a syringe including a vacuum chamber for holding a first substance. There are several ways of achieving vacuum in a closed volume (chamber). One embodiment of the presently disclosed syringe further comprising one or more vacuum bypass channels located in the barrel and/or in the plunger and configured such that the plunger sealably engages the vacuum chamber in at least a first axial position of the plunger inside the vacuum chamber, i.e. the state where a vacuum is retained, and such that fluid communication is established across the plunger in at least a second axial position of the plunger inside the vacuum chamber via said one or more vacuum bypass channels. Thus, the vacuum bypass channel(s) may be configured to break the sealing between the vacuum chamber and the plunger at a predefined axial position of the plunger inside the vacuum chamber. This may for example be provided if said one or more vacuum bypass channels 16 are one or more longitudinal grooves 17 formed in the inner surface of the proximal end of the vacuum chamber as illustrated in FIG. 2. Alternatively the one or more vacuum bypass channels may be formed in the plunger. One or more vacuum bypass channels are configured such that a fluid communication can be provided directly between the vacuum chamber and the ambient atmosphere independent of the position of the plunger, e.g. via a pressure valve located directly at the vacuum chamber.


Substances


The presently disclosed syringe works for a number of different substances in the two chambers. Some types of medication are provided and stored in two separate chambers, and are mixed before use. Such medication may include a solid component and a liquid solvent and are known as two-part formulations. The solid component can be for example a powdered medicament. In one embodiment of the syringe, the chambers are prefilled with first and second substances, wherein the first substance is a dry composition, and wherein the second substance is an aqueous medium. Preferably, the dry composition is placed in the vacuum chamber and the aqueous medium in the reservoir chamber. Similarly, the syringe may be prefilled with first and second substances, wherein the first substance is a dry component of a medicament and wherein the second substance is an aqueous medium in a wet component of said medicament. The presently disclosed syringe is also suitable for being used with a lyophilized substance, such as a lyophilized drug, as the first substance.


Other Barrel and Plunger Related Aspects


The barrel preferably comprises an outlet for disposing the mixed final product. This outlet is preferably closable and/or sealable in order to retain the vacuum in the vacuum chamber. The outlet may e.g. be a Luer type outlet and it is advantageously located at the distal end of the barrel. The outlet may further be formed as a connector portion suitable for connecting with another mating connector, e.g. suitable for connecting a hose to the syringe. The connector portion may be a connector portion of a standard type, such as a Luer lock or Luer slip connector, preferably a male Luer lock or Luer slip connector. The connector portion may be provided with a threaded portion for secure connection with matching connector. This threaded portion may be provided at the inside of the connector portion.


Preferably, the barrel has an open proximal end, wherein the plunger extends through the proximal end, which can be considered to be a standard solution for a syringe. Typically the syringe is configured such that the plunger can be axially displaced through an open proximal end of the barrel.


The volume capacity presently disclosed syringe is scalable by shaping and scaling the barrel and the plunger. The volume of the vacuum chamber and the reservoir chamber can then be selected within the limits of the barrel and the plunger. The volume of the barrel and/or the volume of the vacuum chamber may be between 0.1 and 500 mL, more preferred between 1 and 100 mL, more preferred between 2 and 50 mL, more preferred between 3 and 30 mL, more preferred less than 25 mL, more preferred less than 20 mL, more preferred less than 15 mL, more preferred less than 10 mL, most preferred between 5 and 10 mL.


Correspondingly the volume of the hollow body of the plunger and/or the volume of the reservoir chamber is between 0.1 and 500 mL, more preferred between 1 and 100 mL, more preferred between 2 and 50 mL, more preferred between 3 and 30 mL, more preferred less than 25 mL, more preferred less than 20 mL, more preferred less than 15 mL, more preferred less than 10 mL, most preferred between 5 and 10 mL.


The presently disclosed syringe is preferably a single-use disposable syringe. The different components of the syringe (barrel, plunger, plug, valve, valve part, etc.) are preferably suitable for manufacture by means of single cycle injection molding.


Examples

One embodiment of the presently disclosed syringe 1 is exemplified in FIGS. 1A-1F. The barrel 2 is provided with a vacuum chamber 4, an outlet 3, an outer needle 14 and a barrel flange 12. The plunger 5 has a reservoir chamber 6 and a plunger flange 11. The membrane 7 forms the distal end of the plunger 5. Inside the barrel 2 there is a pointed member 8 attached at the distal end of the barrel 2, the pointed member 8 having a bypass channel 15. The syringe further comprises an (axially slidable) plug 13 inside the plunger 5, sealably engaged with the inside of the plunger 5. The syringe also comprises first and second locking elements 9 and 10, respectively, to lock the positions of the plunger 5 and barrel 2) in relation to each other (i.e. also the positions between the membrane and the pointed member in relation to each other).



FIGS. 1A-F can be said to show a process in which the syringe goes from a preloaded state having two substances separated in the vacuum chamber 4 and the reservoir chamber 6, through a state where the substances are mixed, and finally the mixed substance delivered.


In FIG. 1A the syringe 1 is locked in a first configuration. In this configuration a vacuum generator can be connected to the vacuum chamber 4 and vacuum created, thereby building up inherent energy of the syringe and a vacuum force pulling the plunger 5 towards the vacuum chamber 4. However, the first and second locking element 9 and 10 prevent the plunger from moving.


In FIG. 1B the first locking element 9 has been removed and, as a consequence, the plunger has been pulled by the vacuum force to a second position, where it is blocked from further moving by the second locking element 10. The pointed member 8 has penetrated the membrane 7 and the first substance can start to flow from the reservoir chamber 6 to the vacuum chamber 4 through the bypass channel 15, which is axially aligned with the (penetrated) membrane 7.


In FIG. 10 the content (substance) of the reservoir chamber 6 has been transferred to the vacuum chamber 4, where the two substances have been mixed. The plug 13 has also been pulled by the vacuum force to abut the distal end of the plunger 5.


In FIG. 1D the second locking element 10 has been removed, enabling the possibility to push the plunger 5 further towards the vacuum chamber 4 to eject the mixed content through the outlet 3 and outer needle 14.


In FIG. 1E the plunger 5 has been pushed (or further pulled by the vacuum force) further towards the vacuum chamber 4. Finally, in FIG. 1F the mixed content has been ejected/delivered by pushing plunger 5 in the distal direction to a final position.



FIG. 2 shows the proximal part of the syringe 1 where a first locking element 9 is snap fitted to the proximal end of the plunger 5 restricting that the plunger 5 can be moved in a distal direction into the barrel 2. The barrel 2 comprises vacuum bypass channel 16. The first locking element 9 is provided with longitudinal protrusion 17 adapted to match the vacuum bypass channel 16 in the barrel 2. The first locking element 9 is a rigid plastic element that grabs the proximal part of the plunger 5 and the rigidity and the extension of the locking element 9 locks the plunger 5 in an axial position relative to the barrel 2 defined by the length of the locking element 9. The locking element 9 does not prevent the plunger 5 from moving in a proximal direction out of the barrel 2. However, when a vacuum is retained in the vacuum chamber, the lower pressure of the vacuum will draw the plunger 5 towards the vacuum chamber. I.e. the syringe is configured such that the plunger 5 can be locked in the barrel 2, i.e. restricted from longitudinal/axial movement in both the proximal and distal direction. The longitudinal protrusion 17 in the locking element 9 is adapted to match the vacuum bypass channels 16 in the barrel 2 to provide a rotational lock of the locking element 9 in this locked configuration helping to ensure that the syringe 1 cannot be easily tampered with in the locked configuration.



FIGS. 3A and 3B show illustrations of an exemplary plunger 5 of the presently disclosed syringe. The plunger 5 comprises a plunger flange 11 and a reservoir chamber 6 which is defined by the slidable plug 13 (not shown in FIG. 3). The membrane 7 is attached to the distal end of the plunger 5. The membrane 7 comprises an annular protrusion 20 such that the plunger engages sealingly with the inside of the barrel 2. The membrane 7 further comprises a thin membrane barrier 7′ that can be penetrated by the pointed member 8. The membrane is attached to the plunger by engagement with the circular protrusion 19. The plunger further comprises longitudinal protrusions 18 adapted to match the vacuum bypass channels 16 in the barrel 2 and/or the longitudinal protrusions 17 of the first locking element 9.


Further Details of the Invention





    • 1. A syringe for retaining and mixing first and second substances comprising
      • a barrel comprising a sealable and/or closable distal outlet and a vacuum chamber for holding a first substance,
      • a plunger incorporating a reservoir chamber for holding a second substance and configured to be axially displaced through a proximal end of the barrel,
      • a membrane separating the vacuum chamber and the reservoir chamber, and
      • a pointed member, such as one or more needles, for penetrating the membrane,

    • wherein the syringe is configured such that the membrane and the pointed member are axially slidable in relation to each other.

    • 2. The syringe according to any of the preceding items, wherein the reservoir chamber is (completely) contained in the plunger, and/or wherein the reservoir chamber is at least partly defined by outer walls of the plunger.

    • 3. The syringe according to any of the preceding items, wherein an axial displacement of the plunger relative to the barrel corresponds to an axial displacement of the membrane and the pointed member relative to each other.

    • 4. The syringe according to any of the preceding items, wherein the syringe is configured such that the membrane and the pointed member are axially slidable in relation to each other in correspondence with an axial displacement of the barrel relative to the plunger.

    • 5. The syringe according to any of the preceding items, configured such that an axial displacement of the plunger from a first position to a predefined second position in the barrel penetrates the membrane by the pointed member and establishes a fluid passageway between the reservoir chamber and the vacuum chamber.

    • 6. The syringe according to any of the preceding items 5, whereupon the vacuum in the vacuum chamber aspirates the second substance into the vacuum chamber thereby transferring the content of the reservoir chamber into the vacuum chamber, preferably without displacement of the plunger from said predefined second position.

    • 7. The syringe according to any of the preceding items, configured to retain a vacuum in the vacuum chamber in a first configuration, said first configuration preferably being a storage condition of the syringe.

    • 8. The syringe according to item 7, configured such that in said first configuration the membrane and the pointed member are separated, preferably axially separated inside the barrel.

    • 9. The syringe according to any of the preceding items, configured to provide a liquid communication between the vacuum chamber and the reservoir chamber in a second configuration.

    • 10. The syringe according to item 9, configured such that in said second configuration the pointed member penetrates the membrane.

    • 11. The syringe according to any of the preceding items 9-10, further comprising a liquid bypass arrangement and configured such that said liquid communication between the vacuum chamber and the reservoir chamber is provided by means of said liquid bypass arrangement.

    • 12. The syringe according to any of the preceding items, wherein the membrane is separating a proximal end of the vacuum chamber and a distal end of the reservoir chamber.

    • 13. The syringe according to any of the preceding items, configured such that the pointed member penetrates the membrane upon a distal displacement of the plunger inside the barrel.

    • 14. The syringe according to any of the preceding items, wherein the membrane is attached to and/or forms the distal end of the plunger.

    • 15. The syringe according to any of the preceding items, wherein the pointed member is attached inside the barrel, preferably attached at the distal end of the barrel.

    • 16. The syringe according to any of the preceding items, wherein the pointed member is extending axially inside the barrel.

    • 17. The syringe according to any of the preceding items, wherein the pointed member is extending axially inside the barrel from the distal end of the barrel and pointing towards the proximal end of the barrel.

    • 18. The syringe according to any of the preceding items, wherein the pointed member comprises one or more liquid bypass channels configured to provide liquid communication between the reservoir chamber and the vacuum chamber upon penetration of the membrane.

    • 19. The syringe according to item 18, wherein said liquid communication between the reservoir chamber and the vacuum chamber is provided for predefined axial position of the plunger, preferably only for said predefined axial position.

    • 20. The syringe according to any of the preceding items 18-19, configured such that the membrane and the pointed member form a sealed engagement when the pointed member penetrates the membrane and the membrane is axially separated from said one or more liquid bypass channels.

    • 21. The syringe according to any of the preceding items, further comprising a removable locking member configured to engage and restrict the plunger from distal axial displacement inside the barrel.

    • 22. The syringe according to item 21, wherein the locking member is configured to engage the proximal part of the plunger extending from the proximal end of the barrel.

    • 23. The syringe according to any of the preceding items 21-22, wherein the locking member is configured to engage and restrict the plunger from distal axial displacement inside the barrel in two different axial positions of the plunger relative to the barrel.

    • 24. The syringe according to any of the preceding items 21-23, wherein the locking member comprises a first locking element and a second locking element, each of said locking elements configured to engage and restrict the plunger from distal axial displacement inside the barrel.

    • 25. The syringe according to item 24, wherein the first and second locking elements are configured to engage the plunger in axial extension of each other.

    • 26. The syringe according to any of the preceding items, wherein the first configuration corresponds to a first axial position of the plunger in the barrel and wherein the second configuration corresponds to a second axial position of the plunger in the barrel.

    • 27. The syringe according to any of the preceding items, configured such that the plunger is locked in said first configuration.

    • 28. The syringe according to any of the preceding items, configured such that the plunger is locked in said second configuration.

    • 29. The syringe according to any of the preceding items, configured such that the plunger is restricted from axial displacement in a distal direction in said first configuration, preferably by means of the removable first and second locking elements for engaging and locking the plunger in said first configuration.

    • 30. The syringe according to any of the preceding items, configured such that the plunger is restricted from axial displacement in a distal direction in said second configuration, preferably by means of the removable second locking element adapted for engaging and locking the plunger in said second configuration.

    • 31. The syringe according to any of the preceding items, configured such that upon unlocking the plunger, a vacuum in the vacuum chamber causes an axial displacement of the plunger from a first position to a second position.

    • 32. The syringe according to any of the preceding items, configured such that an axial displacement of the plunger from a first position to a predefined second position penetrates the membrane by the pointed member and establishes a fluid passageway between the reservoir chamber and the vacuum chamber.

    • 33. The syringe according to item 32, wherein the first position is determined by the first and second locking elements engaging the plunger in combination, and wherein the second position is determined by only the second locking element engaging the plunger.

    • 34. The syringe according to any of the preceding items, wherein the plunger is hollow.

    • 35. The syringe according to any of the preceding items, further comprising an axially slidable plug inside the plunger, said plug sealably engaged with the inside of the plunger which is hollow, such that the reservoir chamber is defined by the plug inside the hollow plunger.

    • 36. The syringe according to item 35, wherein the reservoir chamber is located in the distal end of the plunger and defined distally by the distal end of the plunger and proximally by the axially slidable plug.

    • 37. The syringe according to any of the preceding items 35-36, wherein the plug is completely contained within the hollow body of the plunger

    • 38. The syringe according to any of the preceding items 35-37, wherein the plug is recessed within the hollow body of the plunger,

    • 39. The syringe according to any of the preceding items 35-38, wherein the plug is configured to be axially displaced distally within the hollow body of the plunger during discharge/flushing of the second substance in the reservoir chamber into the vacuum chamber.

    • 40. The syringe according to any of the preceding items 35-39, configured such that upon penetration of the membrane and provision of a liquid communication between the vacuum chamber and the reservoir chamber, a vacuum in the vacuum chamber draws liquid contained in the reservoir chamber into the vacuum chamber along with an axial distal displacement of the plug within the hollow body.

    • 41. The syringe according to any of the preceding items 35-40, wherein the axially slidable plug is configured to be penetrated by the pointed member.

    • 42. The syringe according to any of the preceding items, wherein the pointed member is formed as an elongated pointed element wherein one end of the pointed element, preferably the proximal end, is pointed, such as pointed like a needle.

    • 43. The syringe according to any of the preceding items, wherein the pointed member comprises one or more liquid bypass channels.

    • 44. The syringe according to item 43, wherein said one or more liquid bypass channels are located adjacent to the proximal end of the pointed member.

    • 45. The syringe according to any of the preceding items 43-44, wherein said one or more liquid bypass channels are formed as one or more recesses, such as one or more radial recesses, of the pointed member located distal from the proximal part of the pointed element.

    • 46. The syringe according to any of the preceding items 43-45, configured such that in said second configuration and/or second position the at least one of said one or more bypass channels are axially aligned with the membrane.

    • 47. The syringe according to any of the preceding items, further comprising one or more vacuum bypass channels located in the barrel and/or in the plunger and configured such that the plunger sealably engages the vacuum chamber in at least a first axial position of the plunger inside the vacuum chamber, and such that fluid communication is established across the plunger in at least a second axial position of the plunger inside the vacuum chamber via said one or more vacuum bypass channels.

    • 48. The syringe according to any of the preceding items, wherein the syringe is prefilled with first and second substances and wherein the first substance is a dry composition, and wherein the second substance is an aqueous medium.

    • 49. The syringe according to any of the preceding items, wherein the syringe is prefilled with first and second substances and wherein the first substance is a dry component of a medicament and wherein the second substance is an aqueous medium in a wet component of said medicament.

    • 50. The syringe according to any of the preceding items, wherein the first substance is a lyophilized substance, such as a lyophilized drug.

    • 51. The syringe according to any of the preceding items, wherein the barrel comprises an open proximal end.

    • 52. The syringe according to any of the preceding items, configured such that a proximal end of the plunger extends through an open proximal end of the barrel.

    • 53. The syringe according to any of the preceding items, configured such that the plunger can be axially displaced through an open proximal end of the barrel.

    • 54. The syringe according to any of the preceding items, wherein the barrel comprises a sealable/closable outlet, such as a Luer type outlet.

    • 55. The syringe according to any of the preceding items, wherein the barrel comprises a sealable/closable outlet located at the distal end of the barrel.

    • 56. The syringe according to any of the preceding items, wherein the outlet comprises a connector portion at a distal end, such as a Luer type connector portion.

    • 57. The syringe according to any of the preceding items, further comprising a sealed engagement between the plunger and barrel.

    • 58. The syringe according to any of the preceding items, wherein the reservoir chamber is defined by a hollow portion of the plunger.

    • 59. The syringe according to any of the preceding items, wherein the plug is formed as a small plunger adapted to fit and be recessed within the hollow plunger.

    • 60. The syringe according to any of the preceding items, wherein the reservoir chamber and the vacuum chamber are fluidly disconnected in said first configuration.

    • 61. The syringe according to any of the preceding items, wherein the reservoir chamber and the vacuum chamber are fluidly connected in said second configuration.

    • 62. The syringe according to any of preceding items, wherein said one or more vacuum bypass channels are configured to break the sealing between the vacuum chamber and the plunger at a predefined axial position of the plunger inside the vacuum chamber.

    • 63. The syringe according to any of preceding items, wherein said one or more vacuum bypass channels are one or more longitudinal grooves formed in the inner surface of the proximal end of the vacuum chamber.

    • 64. The syringe according to any of preceding items, wherein said one or more vacuum bypass channels are formed in the plunger.

    • 65. The syringe according to any of preceding items, wherein the volume of the barrel and/or the volume of the vacuum chamber is between 0.1 and 500 mL, more preferred between 1 and 100 mL, more preferred between 2 and 50 mL, more preferred between 3 and 30 mL, more preferred less than 25 mL, more preferred less than 20 mL, more preferred less than 15 mL, more preferred less than 10 mL, most preferred between 5 and 10 mL.

    • 66. The syringe according to any of preceding items, wherein the volume of the hollow body of the plunger and/or the volume of the reservoir chamber is between 0.1 and 500 mL, more preferred between 1 and 100 mL, more preferred between 2 and 50 mL, more preferred between 3 and 30 mL, more preferred less than 25 mL, more preferred less than 20 mL, more preferred less than 15 mL, more preferred less than 10 mL, most preferred between 5 and 10 mL.

    • 67. The syringe according to any of preceding items, wherein the barrel, the plunger, the plug, the valve and/or the axially displaceable valve element is/are suitable for manufacture by means of single cycle injection moulding.




Claims
  • 1. A syringe for retaining and mixing first and second substances comprising: a barrel comprising a sealable and/or closable distal outlet and a vacuum chamber for retaining the first substance in a vacuum,a plunger incorporating a reservoir chamber for holding the second substance and configured to be axially displaced through a proximal end of the barrel,a membrane separating the vacuum chamber and the reservoir chamber, anda pointed member for penetrating the membrane,
  • 2. The syringe according to claim 1, configured to retain the vacuum in the vacuum chamber in a first configuration.
  • 3. The syringe according to claim 2, wherein the first configuration corresponds to the first position of the plunger in the barrel and wherein a second configuration corresponds to the predefined second position of the plunger in the barrel.
  • 4. The syringe according to claim 3, configured such that the plunger is locked in said second configuration.
  • 5. The syringe according to claim 2, configured such that the plunger is locked in said first configuration.
  • 6. The syringe according to claim 2, wherein said first configuration is a storage condition of the syringe.
  • 7. The syringe according to claim 1, wherein the pointed member is attached inside the barrel.
  • 8. The syringe according to claim 1, wherein the pointed member is attached at a distal end of the barrel.
  • 9. The syringe according to claim 1, further comprising a removable locking member configured to engage and restrict the plunger from distal axial displacement inside the barrel, said locking member comprising a first locking element and a second locking element, each of said locking elements configured to engage and restrict the plunger from the distal axial displacement inside the barrel.
  • 10. The syringe according to claim 9, wherein the removable locking member is configured to engage and restrict the plunger from the distal axial displacement inside the barrel in two different axial positions of the plunger relative to the barrel: the first position and the predefined second position.
  • 11. The syringe according to claim 10, wherein the two different axial positions of the plunger relative to the barrel correspond to said first position and said predefined second position of the plunger in the barrel, respectively.
  • 12. The syringe according to claim 9, wherein the first and second locking elements are configured to engage the plunger in axial extension of each other.
  • 13. The syringe according to claim 9, configured such that the plunger is restricted from axial displacement in a distal direction in said first configuration by means of the removable first and second locking elements for engaging and locking the plunger in a first configuration.
  • 14. The syringe according to claim 9, configured such that the plunger is restricted from the axial displacement in a distal direction in a second configuration by means of the second locking element adapted for engaging and locking the plunger in the second configuration.
  • 15. The syringe according to claim 1, further comprising an axially slidable plug inside the plunger, said plug being sealably engaged with the inside of the plunger which is hollow, such that the reservoir chamber is defined by the plug inside the hollow plunger.
  • 16. The syringe according to claim 15, wherein the plug is configured to be axially displaced distally within a hollow body of the plunger during discharge/flushing/transfer of the second substance in the reservoir chamber into the vacuum chamber.
  • 17. The syringe according to claim 15, configured such that upon penetration of the membrane and provision of a liquid communication between the vacuum chamber and the reservoir chamber, the vacuum in the vacuum chamber draws the second substance contained in the reservoir chamber into the vacuum chamber along with an axial distal displacement of the plug within the hollow body.
  • 18. The syringe according to claim 1, wherein the pointed member comprises one or more liquid bypass channels configured to provide liquid communication between the reservoir chamber and the vacuum chamber upon penetration of the membrane.
  • 19. The syringe according to claim 18, configured such that the membrane and the pointed member form a sealed engagement when the pointed member penetrates the membrane and the membrane is axially separated from said one or more liquid bypass channels.
  • 20. The syringe according to claim 1, wherein the pointed member comprises one or more liquid bypass channels, said one or more liquid bypass channels formed as at least one recess of the pointed member located distal from a proximal part of the pointed member.
  • 21. The syringe according to claim 20, configured such that in a second configuration and/or the predefined second position the at least one of said one or more bypass channels are axially aligned with the membrane.
  • 22. The syringe according to claim 20, wherein said at least one recess is a radial recess.
  • 23. The syringe according to claim 1, wherein the reservoir chamber is defined by a hollow portion of the plunger and wherein the membrane is attached to and/or forms a distal end of the plunger such that the membrane is separating a proximal end of the vacuum chamber and a distal end of the reservoir chamber.
  • 24. The syringe according to claim 1, wherein the syringe is prefilled with the first and second substances and wherein the first substance is a dry component of a medicament and wherein the second substance is an aqueous medium in a wet component of said medicament.
  • 25. The syringe according to claim 1, wherein the pointed member comprises at least one needle.
Priority Claims (1)
Number Date Country Kind
15175189 Jul 2015 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2016/065260 6/30/2016 WO 00
Publishing Document Publishing Date Country Kind
WO2017/005590 1/12/2017 WO A
US Referenced Citations (417)
Number Name Date Kind
2465357 Correll et al. Mar 1949 A
2465860 Fleischmann Mar 1949 A
2507244 Correll May 1950 A
2558395 Studer Jun 1951 A
2899362 Sieger et al. Aug 1959 A
3089815 Kupelwieser et al. May 1963 A
3224434 Molomut et al. Dec 1965 A
3405712 Pierick Oct 1968 A
3514518 Charier-Vadrot May 1970 A
3608593 McCormick et al. Sep 1971 A
3678933 Moore et al. Jul 1972 A
3815580 Oster Jun 1974 A
3869539 Kring et al. Mar 1975 A
3892876 Hobday et al. Jul 1975 A
3899606 Forkner Aug 1975 A
3930052 De Brou et al. Dec 1975 A
3946732 Hurscham Mar 1976 A
4002173 Manning et al. Jan 1977 A
4006220 Gottlieb Feb 1977 A
4013078 Feild Mar 1977 A
4098728 Rosenblatt et al. Jul 1978 A
4107288 Oppenheim et al. Aug 1978 A
4124705 Rothman et al. Nov 1978 A
4150744 Fennimore Apr 1979 A
4160022 Delaney et al. Jul 1979 A
4164559 Miyata et al. Aug 1979 A
4179400 Tsao et al. Dec 1979 A
4194392 Lombard et al. Mar 1980 A
4208439 Hsu Jun 1980 A
4256877 Karlsson et al. Mar 1981 A
4265233 Sugitachi et al. May 1981 A
4280954 Yannas et al. Jul 1981 A
4291013 Wahlig et al. Sep 1981 A
4292972 Pawelchak et al. Oct 1981 A
4298598 Schwarz et al. Nov 1981 A
4300494 Graiff et al. Nov 1981 A
4320201 Berg et al. Mar 1982 A
4347234 Wahlig et al. Aug 1982 A
4362567 Schwarz et al. Dec 1982 A
4377572 Schwarz et al. Mar 1983 A
4416813 Ikeda et al. Nov 1983 A
4424208 Wallace et al. Jan 1984 A
4453939 Zimmerman Jun 1984 A
4482386 Wittwer et al. Nov 1984 A
4492305 Avery Jan 1985 A
4515637 Cioca May 1985 A
4522302 Paikoff Jun 1985 A
4536387 Sakamoto et al. Aug 1985 A
4540410 Wood et al. Sep 1985 A
4543332 Jao et al. Sep 1985 A
4549554 Markham Oct 1985 A
4554156 Fischer Nov 1985 A
4556156 Frutin Dec 1985 A
4557377 Maloney Dec 1985 A
4559304 Kasai et al. Dec 1985 A
4600574 Lindner et al. Jul 1986 A
4640834 Eibl et al. Feb 1987 A
4655211 Sakamoto et al. Apr 1987 A
4685597 Hirao et al. Aug 1987 A
4696812 Silbering Sep 1987 A
4702737 Pizzino Oct 1987 A
4735616 Eibl et al. Apr 1988 A
4743229 Chu May 1988 A
4746514 Warne May 1988 A
4749689 Miyata et al. Jun 1988 A
4752466 Saferstein et al. Jun 1988 A
4803075 Wallace et al. Feb 1989 A
4818517 Kwee et al. Apr 1989 A
4832686 Anderson May 1989 A
4837285 Berg et al. Jun 1989 A
4851521 Della Valle et al. Jul 1989 A
4861714 Dean, Jr. et al. Aug 1989 A
4863856 Dean, Jr. et al. Sep 1989 A
4885161 Cornell Dec 1989 A
4887743 Blake et al. Dec 1989 A
4891359 Saferstein et al. Jan 1990 A
4920158 Murray et al. Apr 1990 A
4925677 Feijen May 1990 A
4936835 Haaga et al. Jun 1990 A
4946870 Partain, III et al. Aug 1990 A
4948575 Cole et al. Aug 1990 A
4965203 Silbering et al. Oct 1990 A
4982769 Fournier et al. Jan 1991 A
4997753 Dean, Jr. et al. Mar 1991 A
5007916 Linsky et al. Apr 1991 A
5017229 Burns et al. May 1991 A
5023082 Friedman et al. Jun 1991 A
5024841 Chu et al. Jun 1991 A
5037740 Tanaka et al. Aug 1991 A
5041292 Feijen Aug 1991 A
5061274 Kensey Oct 1991 A
5061492 Okada et al. Oct 1991 A
5062834 Gross et al. Nov 1991 A
5080893 Goldberg et al. Jan 1992 A
5108421 Fowler Apr 1992 A
5112750 Tanaka et al. May 1992 A
5126141 Henry Jun 1992 A
5129882 Weldon et al. Jul 1992 A
5134229 Saferstein et al. Jul 1992 A
5135751 Henry et al. Aug 1992 A
5135755 Czech et al. Aug 1992 A
5140016 Goldberg et al. Aug 1992 A
5149540 Kunihiro et al. Sep 1992 A
5162430 Rhee et al. Nov 1992 A
5165938 Knighton Nov 1992 A
5178883 Knighton Jan 1993 A
5180583 Hedner Jan 1993 A
5192300 Fowler Mar 1993 A
5196185 Silver et al. Mar 1993 A
5204382 Wallace et al. Apr 1993 A
5209776 Bass et al. May 1993 A
5219328 Morse et al. Jun 1993 A
5275616 Fowler Jan 1994 A
5281528 Boctor et al. Jan 1994 A
5292362 Bass et al. Mar 1994 A
5300494 Brode, II et al. Apr 1994 A
5304377 Yamada et al. Apr 1994 A
5306501 Viegas et al. Apr 1994 A
5324775 Rhee et al. Jun 1994 A
5328955 Rhee et al. Jul 1994 A
5330446 Weldon et al. Jul 1994 A
5350573 Goldberg et al. Sep 1994 A
5350581 Kochinke Sep 1994 A
5352715 Wallace et al. Oct 1994 A
5356614 Sharma Oct 1994 A
5356883 Kuo et al. Oct 1994 A
5384333 Davis et al. Jan 1995 A
5385606 Kowanko Jan 1995 A
5387208 Ashton et al. Feb 1995 A
5394886 Nabai et al. Mar 1995 A
5397704 Boctor et al. Mar 1995 A
5399361 Song et al. Mar 1995 A
5401511 Margalit Mar 1995 A
5418222 Song et al. May 1995 A
5428022 Palefsky et al. Jun 1995 A
5428024 Chu et al. Jun 1995 A
5437672 Allyne Aug 1995 A
5441491 Verschoor et al. Aug 1995 A
5443481 Lee Aug 1995 A
5447966 Hermes et al. Sep 1995 A
5456693 Conston et al. Oct 1995 A
5462860 Mach Oct 1995 A
5478352 Fowler Dec 1995 A
5503848 Perbellini et al. Apr 1996 A
5507744 Tay et al. Apr 1996 A
5510418 Rhee et al. Apr 1996 A
5512301 Song et al. Apr 1996 A
5514379 Weissleder et al. May 1996 A
5516532 Atala et al. May 1996 A
5520925 Maser May 1996 A
5531759 Kensey et al. Jul 1996 A
5540715 Katsaros et al. Jul 1996 A
5580923 Yeung et al. Dec 1996 A
5595735 Saferstein et al. Jan 1997 A
5599735 Moslehi Feb 1997 A
5614587 Rhee et al. Mar 1997 A
5618551 Tardy et al. Apr 1997 A
5643596 Pruss et al. Jul 1997 A
5645849 Pruss et al. Jul 1997 A
5648506 Desai et al. Jul 1997 A
5658592 Tanihara et al. Aug 1997 A
5660854 Haynes et al. Aug 1997 A
5667839 Berg Sep 1997 A
5669934 Sawyer Sep 1997 A
5672336 Sharma Sep 1997 A
5674275 Tang et al. Oct 1997 A
5690675 Sawyer et al. Nov 1997 A
5690954 Ilium Nov 1997 A
5698213 Jamiolkowski et al. Dec 1997 A
5700476 Rosenthal et al. Dec 1997 A
5712161 Koezuka et al. Jan 1998 A
5714370 Eibl et al. Feb 1998 A
5723308 Mach et al. Mar 1998 A
5743312 Pfeifer et al. Apr 1998 A
5749895 Sawyer et al. May 1998 A
5752974 Rhee et al. May 1998 A
5770229 Tanihara et al. Jun 1998 A
5779668 Grabenkort Jul 1998 A
5791352 Reich et al. Aug 1998 A
5795330 Tofighi et al. Aug 1998 A
5798091 Trevino et al. Aug 1998 A
5804203 Hang et al. Sep 1998 A
5823671 Mitchell et al. Oct 1998 A
5824015 Sawyer Oct 1998 A
5853749 Hobbs Dec 1998 A
5856356 Tsouderos et al. Jan 1999 A
5861043 Carn Jan 1999 A
5863496 McElhany Jan 1999 A
5874500 Rhee et al. Feb 1999 A
5876372 Grabenkort et al. Mar 1999 A
5883078 Seelich et al. Mar 1999 A
5890610 Jansen et al. Apr 1999 A
5895412 Tucker Apr 1999 A
5902832 Van Bladel et al. May 1999 A
5908054 Safabash et al. Jun 1999 A
5931165 Reich et al. Aug 1999 A
5939259 Harvey et al. Aug 1999 A
5951531 Ferdman et al. Sep 1999 A
5951583 Jensen et al. Sep 1999 A
5957166 Safabash Sep 1999 A
5959735 Maris et al. Sep 1999 A
5986168 Noishiki et al. Nov 1999 A
5997895 Narotam et al. Dec 1999 A
6007613 Izoret Dec 1999 A
6027741 Cialdi et al. Feb 2000 A
6042262 Hajianpour Mar 2000 A
6045570 Epstein et al. Apr 2000 A
6056970 Greenawalt et al. May 2000 A
6063061 Wallace et al. May 2000 A
6066325 Wallace et al. May 2000 A
6074663 Delmottet et al. Jun 2000 A
6096309 Prior et al. Aug 2000 A
6099952 Cercone Aug 2000 A
6110484 Sierra Aug 2000 A
6113948 Heath Sep 2000 A
6129761 Hubbell Oct 2000 A
6132759 Schacht et al. Oct 2000 A
6146587 Morgan Nov 2000 A
6162241 Coury et al. Dec 2000 A
6166130 Rhee et al. Dec 2000 A
6168788 Wortham Jan 2001 B1
6171276 Lippe Jan 2001 B1
6179872 Bell et al. Jan 2001 B1
6193670 van Tassel et al. Feb 2001 B1
6218176 Berthold et al. Apr 2001 B1
6224862 Turecek et al. May 2001 B1
6261596 Li et al. Jul 2001 B1
6277394 Sierra Aug 2001 B1
6280727 Prior et al. Aug 2001 B1
6283933 D'Aiessio et al. Sep 2001 B1
6300128 Morota et al. Oct 2001 B1
6303323 Laskey et al. Oct 2001 B1
6312474 Francis et al. Nov 2001 B1
6312725 Wallace et al. Nov 2001 B1
6321951 Frutin Nov 2001 B1
6328229 Duronio et al. Dec 2001 B1
6334865 Redmond et al. Jan 2002 B1
6361551 Torgerson et al. Mar 2002 B1
6364519 Hughes et al. Apr 2002 B1
6387413 Miyata et al. May 2002 B1
6391343 Yen May 2002 B1
6416739 Rogerson Jul 2002 B1
6423037 Hijikata et al. Jul 2002 B1
6454787 Maddalo et al. Sep 2002 B1
6458380 Leaderman Oct 2002 B1
6458386 Schacht et al. Oct 2002 B1
6458889 Trollsas Oct 2002 B1
6461325 Delmotte et al. Oct 2002 B1
6472162 Coelho Oct 2002 B1
6495127 Wallace et al. Dec 2002 B1
6548081 Sadozai et al. Apr 2003 B2
6584858 Miyazawa et al. Jul 2003 B1
6620436 Rolf Sep 2003 B1
6635272 Leaderman Oct 2003 B2
6638538 Hashimoto et al. Oct 2003 B1
6649162 Biering et al. Nov 2003 B1
6706690 Reich et al. Mar 2004 B2
6716435 Farmer et al. Apr 2004 B1
6733774 Stimmeder May 2004 B2
6831058 Ikada et al. Dec 2004 B1
6861046 Appino et al. Mar 2005 B1
6887974 Pathak May 2005 B2
6902543 Cherif-Cheikh Jun 2005 B1
7052713 Stimmeder May 2006 B2
7056722 Coelho Jun 2006 B1
7109163 Pendharkar et al. Sep 2006 B2
7125860 Renier et al. Oct 2006 B1
7320962 Reich et al. Jan 2008 B2
7393674 Jiang et al. Jul 2008 B2
7427607 Suzuki Sep 2008 B2
7435425 Qian et al. Oct 2008 B2
7547446 Qian et al. Jun 2009 B2
7833965 Pendharkar et al. Nov 2010 B2
7871637 Qian et al. Jan 2011 B2
7923431 Wolff Apr 2011 B2
7927626 Pendharkar et al. Apr 2011 B2
7935371 Williams May 2011 B2
8071090 Senderoff et al. Dec 2011 B2
8119160 Looney et al. Feb 2012 B2
8303981 Wallace et al. Nov 2012 B2
8329119 Pearcy Dec 2012 B2
8357378 Wallace et al. Jan 2013 B2
8512729 Wallace et al. Aug 2013 B2
8551941 Pendharkar et al. Oct 2013 B2
8603511 Wallace et al. Dec 2013 B2
8642831 Larsen et al. Feb 2014 B2
8846105 Koopman et al. Sep 2014 B2
9048945 Cordeiro Jun 2015 B2
9265858 Larsen Feb 2016 B2
9376674 Jorquera Nieto et al. Jun 2016 B2
9446848 Jerome et al. Sep 2016 B2
9533069 Larsen et al. Jan 2017 B2
9629798 Senderoff et al. Apr 2017 B2
9724078 Larsen et al. Aug 2017 B2
9999703 Larsen Jun 2018 B2
10111980 Larsen Oct 2018 B2
10595837 Larsen et al. Mar 2020 B2
20010008636 Yamamoto et al. Jul 2001 A1
20010038848 Donda Nov 2001 A1
20010041913 Cragg et al. Nov 2001 A1
20020006429 Redmond et al. Jan 2002 A1
20020010150 Cortese et al. Jan 2002 A1
20020010482 Watt et al. Jan 2002 A1
20020012982 Blakesley et al. Jan 2002 A1
20020015724 Yang et al. Feb 2002 A1
20020019062 Lea et al. Feb 2002 A1
20020025921 Petito et al. Feb 2002 A1
20020026215 Redmond et al. Feb 2002 A1
20020027146 de LaForcade et al. Mar 2002 A1
20020039594 Unger Apr 2002 A1
20020042378 Reich et al. Apr 2002 A1
20020061842 Mansour et al. May 2002 A1
20020072767 Zhu Jun 2002 A1
20020082620 Lee et al. Jun 2002 A1
20020111576 Greene et al. Aug 2002 A1
20020164322 Schaufler Nov 2002 A1
20020173818 Reever Nov 2002 A1
20020188196 Burbank et al. Dec 2002 A1
20020192271 Hedner et al. Dec 2002 A1
20020193448 Wallace et al. Dec 2002 A1
20030004449 Lafratta et al. Jan 2003 A1
20030008831 Yang et al. Jan 2003 A1
20030009194 Saker et al. Jan 2003 A1
20030012741 Furlan et al. Jan 2003 A1
20030028140 Greff Feb 2003 A1
20030032143 Neff et al. Feb 2003 A1
20030040701 Dalmose Feb 2003 A1
20030064109 Qian et al. Apr 2003 A1
20030095993 Benz et al. May 2003 A1
20030162708 Wolff Aug 2003 A1
20030175410 Campbell Sep 2003 A1
20030175419 Sessa Sep 2003 A1
20030181659 Naranda et al. Sep 2003 A1
20030224056 Kotha et al. Dec 2003 A1
20030225378 Wilkie et al. Dec 2003 A1
20030232746 Lamberti et al. Dec 2003 A1
20040062790 Constantine et al. Apr 2004 A1
20040076647 Biering Apr 2004 A1
20040079763 Powell et al. Apr 2004 A1
20040101546 Gorman et al. May 2004 A1
20040120993 Zhang et al. Jun 2004 A1
20040186432 Barry et al. Sep 2004 A1
20040197388 Sceusa Oct 2004 A1
20040214770 Reich et al. Oct 2004 A1
20040243043 McCarthy et al. Dec 2004 A1
20040267352 Davidson et al. Dec 2004 A1
20050008632 Stimmeder Jan 2005 A1
20050031691 McGurk et al. Feb 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050171001 Pendharkar et al. Aug 2005 A1
20050186253 Lee et al. Aug 2005 A1
20050214277 Schaufler Sep 2005 A1
20050218541 Peng et al. Oct 2005 A1
20050239675 Makansi Oct 2005 A1
20050245905 Schmidt et al. Nov 2005 A1
20050284809 Looney et al. Dec 2005 A1
20060002890 Hersel et al. Jan 2006 A1
20060002918 Jiang et al. Jan 2006 A1
20060052747 Nishimura Mar 2006 A1
20060067976 Ferraro et al. Mar 2006 A1
20060068013 DiTizio et al. Mar 2006 A1
20060115805 Hansen Jun 2006 A1
20060121080 Lye et al. Jun 2006 A1
20060121104 Stern Jun 2006 A1
20060147492 Hunter et al. Jul 2006 A1
20060159733 Pendharkar et al. Jul 2006 A1
20060167561 Odar et al. Jul 2006 A1
20060189516 Yang et al. Aug 2006 A1
20060193846 Stimmeder Aug 2006 A1
20060204490 Pendharkar et al. Sep 2006 A1
20060255053 Li Nov 2006 A1
20060282138 Ota Dec 2006 A1
20070009578 Moiler et al. Jan 2007 A1
20070025955 Lowinger et al. Feb 2007 A1
20070054020 Kumagai Mar 2007 A1
20070086958 Drake et al. Apr 2007 A1
20070128343 Chappa Jun 2007 A1
20070160543 Moiler Jul 2007 A1
20070215235 Ranalletta et al. Sep 2007 A1
20070217282 Lidgren Sep 2007 A1
20070250007 Shekalim Oct 2007 A1
20070264130 Mallett Nov 2007 A1
20070264301 Cleek et al. Nov 2007 A1
20070264302 Cleek et al. Nov 2007 A1
20080029087 Kidd, III Feb 2008 A1
20080085316 Qian et al. Apr 2008 A1
20080091277 Deusch et al. Apr 2008 A1
20080095830 Van Holten Apr 2008 A1
20080109002 Delmotte May 2008 A1
20080199539 Baker et al. Aug 2008 A1
20080286376 Qian et al. Nov 2008 A1
20080311172 Schapira et al. Dec 2008 A1
20090087569 Fan et al. Apr 2009 A1
20090142396 Odar et al. Jun 2009 A1
20090157017 Ambrosio Jun 2009 A1
20100028309 Odar et al. Feb 2010 A1
20100048758 Chen et al. Feb 2010 A1
20100063459 Preiss-Bloom et al. Mar 2010 A1
20100113828 Dalsin et al. May 2010 A1
20100143447 Hansen Jun 2010 A1
20100256671 Falus Oct 2010 A1
20100292717 Petter-Puchner et al. Nov 2010 A1
20100318048 Hoeffinghoff et al. Dec 2010 A1
20110021964 Larsen et al. Jan 2011 A1
20110045034 Nur et al. Feb 2011 A1
20110059228 Gillick et al. Mar 2011 A1
20110270167 Matusch Nov 2011 A1
20120128653 Goessl et al. May 2012 A1
20120201726 Pearcy et al. Aug 2012 A1
20140220130 Larsen et al. Aug 2014 A1
20150037314 Larsen Feb 2015 A1
20150045830 Jensen et al. Feb 2015 A1
20160120527 Larsen et al. May 2016 A1
20160354512 Larsen Dec 2016 A1
20180243468 Larsen Aug 2018 A1
20180264194 Larsen Sep 2018 A1
20190015546 Larsen Jan 2019 A1
Foreign Referenced Citations (214)
Number Date Country
0051589 Jul 1993 BG
0099900 Mar 1997 BG
1270240 Oct 2000 CN
2316209 Oct 1974 DE
3146841 Jun 1983 DE
4119140 Dec 1992 DE
4407875 Sep 1995 DE
0132983 Feb 1985 EP
0156649 Oct 1985 EP
0282316 Sep 1988 EP
0341007 Nov 1989 EP
0341745 Nov 1989 EP
0365705 May 1990 EP
0372966 Jun 1990 EP
0385916 Sep 1990 EP
0395758 Nov 1990 EP
0172710 Mar 1992 EP
0478827 Apr 1992 EP
0493387 Oct 1993 EP
0376931 Jun 1994 EP
0702081 Mar 1996 EP
0737467 Oct 1996 EP
0612252 May 1999 EP
0773740 Nov 1999 EP
1005874 Jun 2000 EP
1022031 Jul 2000 EP
1044693 Oct 2000 EP
1053758 Nov 2000 EP
1084720 Mar 2001 EP
1140235 Oct 2001 EP
1174463 Jan 2002 EP
1258256 Nov 2002 EP
1283063 Feb 2003 EP
0790823 Jul 2003 EP
0891193 Aug 2003 EP
1484070 Dec 2004 EP
1 543 842 Jun 2005 EP
1095064 Jun 2005 EP
1649867 Apr 2006 EP
1361906 Apr 2007 EP
1414370 Apr 2007 EP
1059957 Aug 2007 EP
1608230 Jul 2010 EP
2 040 724 Oct 2011 EP
2679772 May 1993 FR
2759980 Aug 1998 FR
648619 Jan 1951 GB
697603 Sep 1953 GB
1037937 Aug 1966 GB
1199887 Jul 1970 GB
1 483 002 Jul 1975 GB
1584080 Feb 1981 GB
1591654 Jun 1981 GB
2266239 Oct 1993 GB
2393120 Mar 2004 GB
2414021 Nov 2005 GB
51-125156 Nov 1976 JP
59-113889 Jun 1984 JP
60214728 Oct 1985 JP
62070318 Mar 1987 JP
62221357 Sep 1987 JP
01130519 May 1989 JP
05308969 Nov 1993 JP
06254148 Sep 1994 JP
H07090241 Apr 1995 JP
08-024325 Jan 1996 JP
9-504719 May 1997 JP
10-507666 Jul 1998 JP
2002513308 May 2002 JP
2004002271 Jan 2004 JP
2004147959 May 2004 JP
2006-296896 Nov 2006 JP
2010228932 Oct 2010 JP
2011212182 Oct 2011 JP
910007847 Oct 1991 KR
100751046 Aug 2007 KR
WO 8301244 Apr 1983 WO
WO 8600912 Feb 1986 WO
WO 8902730 Apr 1989 WO
WO 9013320 Nov 1990 WO
WO 9221354 Dec 1992 WO
WO 9222252 Dec 1992 WO
WO 9306802 Apr 1993 WO
WO 9306855 Apr 1993 WO
WO 9310768 Jun 1993 WO
WO 9321908 Nov 1993 WO
WO 9408552 Apr 1994 WO
WO 9417840 Aug 1994 WO
WO 9427630 Dec 1994 WO
WO 9512371 May 1995 WO
WO 9515747 Jun 1995 WO
WO 9525748 Sep 1995 WO
WO 9531955 Nov 1995 WO
WO 9604025 Feb 1996 WO
WO 9606883 Mar 1996 WO
WO 9607472 Mar 1996 WO
WO 9610374 Apr 1996 WO
WO 9610428 Apr 1996 WO
WO 9612447 May 1996 WO
WO 9614368 May 1996 WO
WO 9616643 Jun 1996 WO
WO 9639159 Dec 1996 WO
WO 9640033 Dec 1996 WO
WO 9717023 May 1997 WO
WO 9717024 May 1997 WO
WO 9717025 May 1997 WO
WO 9729792 Aug 1997 WO
WO 9737694 Oct 1997 WO
WO 9808550 Mar 1998 WO
WO 9831403 Jul 1998 WO
WO 9834546 Aug 1998 WO
WO 9836784 Aug 1998 WO
WO 9843092 Oct 1998 WO
WO 9844963 Oct 1998 WO
WO 9851282 Nov 1998 WO
WO 9904828 Feb 1999 WO
WO 9912032 Mar 1999 WO
WO 9913902 Mar 1999 WO
WO 9938606 Aug 1999 WO
WO 9944901 Sep 1999 WO
WO 9945938 Sep 1999 WO
WO 99051208 Oct 1999 WO
WO 0009018 Feb 2000 WO
WO 0018301 Apr 2000 WO
WO 0027327 May 2000 WO
WO 0061201 Oct 2000 WO
WO 0074742 Dec 2000 WO
WO 0076533 Dec 2000 WO
WO 0113956 Mar 2001 WO
WO 0128603 Apr 2001 WO
WO 0134206 May 2001 WO
WO 0154735 Aug 2001 WO
WO 0166161 Sep 2001 WO
WO 0197826 Dec 2001 WO
WO 0197871 Dec 2001 WO
WO 0218450 Mar 2002 WO
WO 0222059 Mar 2002 WO
WO 0222184 Mar 2002 WO
WO 0240068 May 2002 WO
WO 02058749 Aug 2002 WO
WO 02064182 Aug 2002 WO
WO 02070594 Sep 2002 WO
WO 02072128 Sep 2002 WO
202096488 Dec 2002 WO
WO 03007845 Jan 2003 WO
WO 2003004072 Jan 2003 WO
WO 03024426 Mar 2003 WO
WO 03024429 Mar 2003 WO
WO 03055531 Jul 2003 WO
WO 2003070110 Aug 2003 WO
WO 03074103 Sep 2003 WO
WO 03094983 Nov 2003 WO
WO 04028404 Apr 2004 WO
WO 04028423 Apr 2004 WO
WO 04029095 Apr 2004 WO
WO 04030711 Apr 2004 WO
WO 2004026377 Apr 2004 WO
WO 2004028583 Apr 2004 WO
WO 2004035629 Apr 2004 WO
WO 2004053051 Jun 2004 WO
WO 2004069303 Aug 2004 WO
WO 04075650 Sep 2004 WO
WO 04084869 Oct 2004 WO
WO 04108035 Dec 2004 WO
WO 2004108179 Dec 2004 WO
WO 2004108418 Dec 2004 WO
WO 05000265 Jan 2005 WO
WO 2005002510 Jan 2005 WO
WO 05009225 Feb 2005 WO
WO 05041811 May 2005 WO
WO 05044285 May 2005 WO
WO 05062889 Jul 2005 WO
WO 05063217 Jul 2005 WO
WO 2005072700 Aug 2005 WO
WO 2005084650 Sep 2005 WO
WO 05107713 Nov 2005 WO
WO 2006005340 Jan 2006 WO
WO 2006031358 Mar 2006 WO
WO 06034568 Apr 2006 WO
WO 06063758 Jun 2006 WO
WO 2006058435 Jun 2006 WO
WO 06128471 Dec 2006 WO
WO 2007001926 Jan 2007 WO
WO 2007018887 Feb 2007 WO
WO 2007092618 Aug 2007 WO
WO 2007133699 Nov 2007 WO
WO 2007137839 Dec 2007 WO
2008019127 Feb 2008 WO
WO 2008016983 Feb 2008 WO
2008060475 May 2008 WO
WO 2008051758 May 2008 WO
WO 2008090555 Jul 2008 WO
WO 2009020612 Feb 2009 WO
WO 2009109194 Sep 2009 WO
WO 2009109963 Sep 2009 WO
WO 2009131752 Oct 2009 WO
WO 2011047753 Apr 2011 WO
WO 2011137437 Nov 2011 WO
WO 2011151384 Dec 2011 WO
WO 2011151386 Dec 2011 WO
WO 2011151400 Dec 2011 WO
WO 2012146655 Nov 2012 WO
WO 2013053753 Apr 2013 WO
WO 2013053755 Apr 2013 WO
WO 2013053759 Apr 2013 WO
WO 2013060770 May 2013 WO
WO 2013112579 Aug 2013 WO
WO 2013131520 Sep 2013 WO
WO 2013185776 Dec 2013 WO
WO 2014086996 Jun 2014 WO
WO 20140202760 Dec 2014 WO
WO 2015086028 Jun 2015 WO
WO 2016058612 Apr 2016 WO
WO 2017098493 Jun 2017 WO
Non-Patent Literature Citations (265)
Entry
Notice of Allowability for U.S. Appl. No. 14/980,254, titled: “Dry Haemostatic Composition”, dated Feb. 13, 2018.
Office Action for U.S. Appl. No. 15/102,994, titled: “Dry Composition Comprising an Extrusion Enhancer”, dated Feb. 22, 2018.
Notice of Allowance for U.S. Appl. No. 15/102,994, titled: “Dry Composition Comprising an Extrusion Enhancer”, dated Jun. 22, 2018.
Office Action for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Aug. 8, 2018.
Final Office Action for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Nov. 30, 2018.
Final Office Action for U.S. Appl. No. 14/383,461, titled: “Pressurized Container Containing Haemostatic Paste”, dated Jan. 8, 2019.
Office Action for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated May 8, 2019.
“Formulation and Evaluation of Absorbable Gelatin Sponges,” Chapter 3A of Rupali Kale thesis: Design and Development of Surgical Dressings for Advanced Wound Management (2010).
“Gelfoam Prescribing Information,” Pharmacia & Upjohn (Nov. 1996).
“Gelfoam® Product Brochure,” Pharmacia & Upjohn (Jun. 2013).
26th Annual Symposium: Clinical Update in Anaesthesiology, Surgery and Perioperative Medicine, Jan. 20-25, 2008.
Ansell, J., et al., “Gelfoam and Autologous Clot Embolization: Effect on Coagulation,” Investigative Radiology, 13: 115-120 (1978).
Arai, K., et al., “Clinical Effect of Thrombin-Collagen Sponge Sheet in Surgical Field,” Chiryo (Pharmacology and Treatment), 11(5):413-418 (1983). (English translation of Office Action for Japanese counterpart application 2010-547957, Title: Device for Promotion of Hemostasis and/or Wound Healing, being provided to satisfy “concise explanation” requirement under 37 C.F.R. 1.98(a)(3)).
Barrow, D.L., et al., “The Use of Greater Omentum Vascularized Free Flaps for Neurosurgical Disorders Requiring Reconstruction”, Journal of Neurosurgery, 60: 305-311 (1984).
Barton, B., et al., “Fibrin Glue as a Biologic Vascular Patch—A Comparative Study,” Journal of Surgical Research, vol. 40, 1 page; abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001. (1986).
Baxter, “Product Catalogue: Collagen,” 4 pages, retrieved from http://www.baxter-ecommerce.com/ecatalog on Feb. 2, 2006 (2006).
Baxter, “TissuFleece E Package Leaflet,” Baxter International Inc., 4 pages, English portion of instructions for use (2003).
Baxter, “TissuFleece E, TissuCone E and TissuFoil E: Biomaterials,” Basic scientific Information, 9 pages (2003).
Boland, T., et al., “Application of Inkjet Printing to Tissue Engineering,” Biotechnol. J., 1: 910-917 (2006).
Boyers, S., et al., “Reduction of Postoperative Pelvic Adhesions in the Rabbit with Gore-Tex Surgical Membrane”, Fertility and Sterility, 49(6,): 1066-1070 (1988).
Brannon-Peppas, L., et al., “The Equilibrium Swelling Behavior of Porous and Non-Porous Hydrogels,” Absorbent Polymer Technology, Elsevier, Amsterdam, pp. 67-102 (1990).
Branski, R.C., et al., “Mucosal Wound Healing in a Rabbit Model of Subglottic Stenosis”; Arch Otolaryngol Head Neck Surg, vol. 131, Feb. 2005, p. 153-157.
Brunt and Klausner, “Growth factors speed wound healing”, Nature Biotechnology, 6(1): 25-30 (1988).
Campbell, P.G., et al., “Engineered Spatial Patterns of FGF-2 Immobilized on Fibrin Direct Cell Organization,” Biomaterials, 26: 6762-6770 (2005).
Campbell, P.G., et al., “Tissue Engineering with the Aid of Inkjet Printers,” Expert Opin. Biol. Ther., 7: 1123-1127 (2007).
Canal, T., et al., “Correlation Between Mesh Size and Equilibrium Degree of Swelling of Polymeric Networks” Biomedical Materials Research, 23: 1183-1193 (1989).
Cantor, M.O., et al., “Gelfoam® and Thrombin in treatment of massive gastroduodenal hemorrhage—A preliminary report”, American Journal of Surgery, 883-887 (Dec. 1950).
Cantor, M.O., et al., “Gelfoam and Thrombin in Gastroduodenal Bleeding: An Experimental Study,” Journal of Laboratory and Clinical Medicine, 35(6): 890-893 (1950).
Cantor, M.O., et al., “Gelfoam and Thrombin in Treatment of Massive Upper Gastrointestinal Hemorrhage,” American Journal of Surgery, 82(2): 230-235 (Aug. 1951).
Cascone, M.G., et al., “Collagen and hyaluronic acid based polymeric blends as drug delivery systems for the release of physiological concentrations of growth hormone.” Journal of Materials science: Materials in Medicine; 5: 770-774 (1994).
Changez, M., et al., Abstract of “Efficacy of antibiotics-loaded interpenetrating network (IPNs) hydrogel based on poly (acrylic acid) and gelatin for treatment of experimental osteomyelitis: in vivo study.”, Biomaterials; 26(14): 2095-2104 (2005).
Chaplin, J .M., et al., “Use of an Acellular Dermal Allograft for Dural Replacement: An Experimental Study,” Neurosurgery, 45(2): 320-327 (1999).
Cheung, D., et al., “Mechanism of Crosslinking of Proteins by Glutaraldehyde IV: In Vitro and In Vivo Stability of a Crosslinked Collagen Matrix,” Connective Tissue Research, 25: 27-34 (1990).
Choi, Y.S., et al., “Studies on Gelatin-Based Sponges. Part Ill: A Comparative Study of Cross-linked Gelatin/ Alginate, Gelatin/ Hyaluronate and Chitosan/Hyaluronate Sponges and their Application as a wound dressing in fullthickness skin defect of rat.”, J. of Mat. Sci.; Mat. in Med.; 12: 67-73 (Jan. 2001).
Choi, Y.S., et al., “Studies on gelatin-containing artificial skin: II. Preparation and characterization of cross-linked gelatin-hyaluronate sponge.”, J. Biomed Mater Res., 48: 631-639 (1999).
Christensen, F, et al., “Qualitative Description of the Wurster-Based Fluid-Bed Coating Process,” Drug Dev and Industry Pharmacy, 23(5): 451-463 (1977).
Chronic Wound Care Guidelines © 2007 http://woundheal.org.documents/final_pocket_guide_treatment.aspx.
Chuang, V.P., et al., “Sheath Needle for Liver Biopsy in High-Risk Patients” Radiology, 166: 261-262 (1988).
Coenye, K.E., et al., “A Qualitative Morphological comparison of Two Heamostatic Agents in a Porcine Liver Trauma Model,” Surgical Science, 4: 359-364 (2013).
Collins, D., et al., “Enemata of Gelfoam Milk Suspension Combined with Thrombin-Solution to Control Massive Hemorrhage Following Anorectal Surgery,” The American Journal of Proctology, 2: 60-63 (1951).
Collins, R., et al., “Use of Collagen Film as a Dural Substitute: Preliminary Animal Studies,” Journal of Biomedical Materials Research, 25: 267-276 (1991).
De la Torre, R.A., et al., “Hemostasis and Hemostatic agents in minimally invasive surgery”, Surgery, 142(4S): S39-S45 (2007).
De laco, P.A., et al., “Efficacy of a Hyaluronan Derivative gel in postsurgical adhesion prevention in the presence of inadequate hemostasis.” Surgery, 130(1): 60-64 (2001).
DeLustro, F., et al., “A Comparative Study of the Biologic and Immunologic Response to Medical Devices Derived From Dermal Collagen,” Journal of Biomedical Materials Research, 20: 109-120 (1986).
Dembo, M.A., et al., Abstract of “Antiseptic hemostatic preparations, their properties and study”, Lech. Prep. Krovi Tkanei; pp. 139-140 (1974).
Dodd, G.D., et al., “Minimally invasive treatment of malignant hepatic tumors. At the threshold of a major breakthrough”, Radiographies, 20: 9-27 (2000).
Drognitz, O., et al., Abstract of “Release of vancomycin and teicoplanin from a plasticized and resorbable gelatin sponge: in vitro investigation of a new antibiotic delivery system with glycopeptides”; lndection Germany (Minich); 34(1): 29-34 (2006).
Duchene, D., et al., “Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration,” Drug Dev and Industr Pharmacy, 14(2&3):283-318 (1988).
Edgerton, M., et al., “Vascular Hamatomas and Hemagiomas: Classification and Treatment,” Southern Medical Journal, 75(12): 1541-1547 (1982).
Ellegala, D.B., et al., “Use of FloSeal Hemostatic Sealant in Transsphenoidal Pituitary Surgery: Technical Note.”; Neurosurgery, 51: 513-516 (Aug. 2002).
English Derwent Abstract of Ranjane reference, Nov. 18, 1997.
Filippi, R., et al., “Bovine Pericardium for Duraplasty: Clinical Results in 32 Patients,” Neurological Review, 20:103-107 (2001).
Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Feb. 26, 2015 “Dry Haemostatic Composition”.
Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Oct. 29, 2015.
Final Office Action for U.S. Appl. No.: 14/383,461, titled: “Pressurized Container Containing Haemostatic Paste”, dated Dec. 14, 2017.
Fiss, I., et al., “Use of Gelatin-Thrombin Hemostatic Sealant in Cranial Neurosurgery,” Neurologia Medico-Chirurgica, 47(10):462-467 (2007).
Flory, P., “Phase Equilibria in Polymer Systems,” Principles of Polymer Chemistry, 13: 541-594 (1953).
FloSeal Matrix Hemostatic Sealant, Instructions for Use, Retrieved from Internet URL http://www.ctsnet.org/file/vendors/931/pdf/140.pdf [retrieved on Aug. 17, 2005].
Fujii, Y., et al., “Safety of GT XIII (Report 2)—Japanese + English translation,” The Clinical Report, 20(17) (Dec. 1986).
Gall, R.M., “Control of Bleeding in Endoscopic Sinus Surgery: Use of a Novel Gelatin-Based Hemostatic Agent”, Journal of Otolaryngology, 31(5): (2002).
Gelfoam absorbable powder. Retrieved from Internet URL: http://www.fda.gov/cdrh/pdf/N18286S012c.pdf [retrieved on May 22, 2009].
Gibble, J.W., et al., “Fibrin glue: the perfect operative sealant?” Reviews: Transfusion, 30(8): 741-747 (1990).
Guinto, F., “Preparation of Gelfoam Particles Using an Orthopedic Rasp,” Radiology, 153: 250 (1984).
Gurny, R., et al.,“Bioadhesive Intraoral Release Systems: Design, Testing and Analysis,” Biomaterials, 5: 336-340 (1984).
Hae-Won, K., et al., Abstract of “Porus scaffolds of gelatin-hydroxyapatite nanocomposites obtained by biometic approach: Characterization and antibiotic drug release.”; J. of Biomedical Materials Research, 74B(2): 686-698 (2005).
Harris, W.H., et al., “Topical Hemostatic Agents for Bone Bleeding in Humans,” The Journal of Bone and Joint Surgery, 60-A(4): 454-456 (1978).
Heller, J., et al., “Release of Norethindrone from Poly(Ortho Esters),” Polymer Engineering and Science, 21: 727-731 (1981).
Herndon, J., et al., “Compression of the Brain and Spinal Cord Following Use of Gelfoam,” Arch. Surg, 104: 107 (Jan. 1972).
Hieb, L., et al, “Spontaneous Postoperative Cerebrospinal Fluid Leaks Following Application of Anti-Adhesion Barrier Gel,” Spine, 26(7): 748-751 (2001).
Hill, et al., “Use of microfibrillar collagen hemostat (avitenet) and thrombin to achieve hemostats after median sternotomy.”; J. Thorac Cardiovasc Surg., 108: 1151-1152 (1994).
Hill-West, J.L., et al., “Efficiacy of a resorbable hydrogel barrier, oxidized regenerated cellulose and hyaluronic acid in the prevention of ovarian adhesions in a rabbit model.”; Fertility and Sterility, 62(3): 630-634 (1994).
Hong, S.R., et al., Abstract of “Study on gelatin-containing artificial skin IV: a comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing.”; Biomaterials, 22(20): 2777-2783 (2001).
Hong, Y.M., et al., “The Use of Hemostatic Agents and Sealants in Urology”, The Journal of Urology, 176: 2367-2374 (2006).
Hood, D., et al., “Efficacy of Topical Hemostat Floseal Matrix in Vascular Surgery,” 24th World Congress of the International Society for Cardiovascular Surgery, Sep. 12-16, 1999, 2 pages.
Hotz, G., et al., “Collagen and Fibrin as Biologic Binders from Granular Hydroxyapatite,” Deutsche Zeitschrift fur Mund-Kieferund Gesichts-Chirurgie, 13(4): 296-300 (1989). Abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001.
International Preliminary Examination Report for International Application No. PCT/DK03/00855, “Gelatine-Based Materials as Swabs”, completed Jun. 2, 2005.
International Preliminary Report on Patentability (Corrected Version) for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, completed Nov. 6, 2006.
International Preliminary Report on Patentability for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, completed Aug. 16, 2006.
International Preliminary Report on Patentability for International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”, completed May 29, 2009.
International Preliminary Report on Patentability for International Application No. PCT/DK2009/050048, “Device for Promotion of Hemostasis and/or Wound Healing”, completed Sep. 6, 2010.
International Preliminary Report on Patentability for International Application No. PCT/DK2013/050054, “Pressurized Container Containing Haemostatic Paste”, dated Sep. 9, 2014.
International Preliminary Report on Patentability from counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Jul. 6, 2012.
International Search Report & Written Opinion of the International Searching Authority for International Application No. PCT/DK2007/050196, “Wound or Tissue Dressing Comprising Lactic Acid Bacteria”, dated Apr. 23, 2008.
International Search Report and Written Opinion of the International Searching Authority from counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Jun. 21, 2011.
International Search Report for International Application No. PCT/DK2003/000855, “Gelatine-Based Materials as Swabs”, dated Oct. 8, 2004.
International Search Report for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, dated Jul. 28, 2005.
International Search Report for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, dated Oct. 25, 2005.
International Search Report for International Application No. PCT/DK2009/050048, “Device for Promotion of Hemostasis and/or Wound Healing”, dated Apr. 6, 2010.
International Search Report for International Application No. PCT/DK2013/050054, “Pressurized Container Containing Haemostatic Paste”, dated Sep. 10, 2013.
International Search Report for International Application No. PCT/DK2013/050191, “Dry Haemostatic Composition”, dated Aug. 21, 2013.
Jeong, B., et al., “Biodegradable Block Copolymers as Injectable Drug-Delivery Systems,” Nature, 388: 860-862 (1997).
Jonas, R., et al., “A new sealant for knitted Dacron prostheses: Minimally cross-linked gelatin,” Journal of Vascular Surgery, 7(3): 414-419 (1988).
Katayama, T., et al., “GT XIII safety (3rd report)—Japanese + English translation,” The Clinical Report, vol. 20 (1986).
Kelly M.J. et al., “The value of an operative wound swab sent in transport medium in the prediction of later clinical wound infection: A controlled clinical and bacteriological evaluation.”, Brit. J. Surgery, 65: 81-88 (1978).
Kim, K., et al., “Reduction in Leg Pain and Lower-Extremity Weakness with Oxiplex/SP Gel for 1 Year after Laminevtomy, Laminotomy, and Disectomy,” Neurosurgical Focus, 17: 1-6 (2004).
Kline, D., et al., “Dural Replacement with Resorbable Collagen,” Archives of Surgery, 91: 924-929 (1965).
Knopp, U., “A New Collagen Foil Versus a Cadaveric Dura Graft for Dural Defects—A Comparative Animal Experimental Study,” European Association of Neurosurgical Societies—Proceedings of the 12th European Congress of Neurosurgery, Lisbon, 17 pages. (2003).
Koçak, I., et al., “Reduction of adhesion formation with cross-linked hyaluronic acid after peritoneal surgery in rats.”, Fertility and Sterility, 72(5): 873-878 (1999).
Kofidis, T., et al., “Clinically Established Hemostatis Scaffold (Tissue Fleece) as Biomatrix in Tissue and Organ Engineering Research,” Tissue Engineering, 9: 517-523 (2003).
Kost J., and Langer R., “Equilibrium Swollen Hydrogels in Controlled Release Applications,” Ch. 5: Hydrogels in Medicine and Pharmacy, vol. III: properties and Applications, N. Peppas ed., pp. 95-108 (1987).
Krill, D., et al., “Topical Thrombin and Powdered Gelfoam: An Efficient Hemostatic Treatment for Surgery,” Journal of Tennessee Dental Association, 66(2): 26-27 (1986).
Kuhn, J., et al., “Bilateral Subdural Heamatomata and Lumbar Pseudomeningocele Due to a Chronic Leakage of Liquor Cerebrospinalis after a Lumbar Disectomy with the Application of ADCON-L Gel,” Journal of Neurology, Neurosergery & Psychiatry, 76: 1031-1033 (2005).
Langer, R., et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” Journal of Macromolecular Science-Reviews in Macromolecular Chemistry and Physics, C23: 61-126 (1983).
Laquerriere, A., et al., “Experimental Evaluation of Bilayered Human Collagen as a Dural Substitute,” Journal of Neurosurgery, 78: 487-491 (1993).
Larson, P., “Topical Hemostatic Agents for Dermatologic Surgery,” Journal of Dermatologic Surgery & Oncology, 14: 623-632 (1988).
Larsson, B., et al., “Surgicel®—an absorbable hemostatic material—in prevention of peritoneal adhesion in rats.”; Acta Chir Scand., 26(144): 375-378 (1978).
Laurent, C., et al., “Hyaluronic acid reduces connective tissue formation in middle ears filled with absorbable gelatin sponge: An experimental study.”, Am. J.Otolaryngol, 7: 181-186 (1986).
Le, A., et al., “Unrecognized Durotomy After Lumbar Discectomy: A Report of Four Cases Associated with the Use of ADCON-L,” Spine, 26(1): 115-118 (2001).
Lee, J., et al., “Experimental Evaluation of Silicone-Coated Dacron and Collagen Fabric-Film Laminate as Dural Substitutes,” Journal of Neurosurgery, 27: 558-564 (1967).
Lee, P., “Interpretation of Drug-Release Kinetics from Hydrogel Matrices in Terms of Time-Dependent Diffusion Coefficients,” Controlled-Release Technology—Pharmaceutical Applications, Ch. 5, ACS Symposium Series 348, pp. 71-83 (1986).
Leong, K., et al., “Polyanhydrides for Controlled Release of Bioactive Agents,” Biomaterials, 7: 364-371 (1986).
Leong, K., et al., “Polymeric Controlled Drug Delivery,” Advanced Drug Delivery Reviews, 1: 199-233 (1987).
Lewis, K., et al., “Comparison of Two Gelatin and Thrombin Combination Hemostats in a Porcine Liver Abrasion Model,” Journal of Investigative Surgery, 26: 141-148 (2013).
Li, G., et al., “Evaluation of esterified hyaluronic acid as middle ear-packing material.”, Arch Otolaryngol Head Neck Surg, 127: 534-539 (2001).
Loeb, J, “The Influence of Electrolytes Upon the Osmotic Pressure of Gelatin Solutions”, J. Biol. Chem., 35: 497-508 (1918).
Luengo, J., et al., “Prevention of peritoneal adhesions by the combined use of Spongostan and 32% Dextran 70: An experimental study in pigs.” Fertility and Sterility, 29(4): 447-450 (1978).
Masar, E., et al., “Synthesis of Polyurethanes and Investigation of their Hydrolytic Stability,” Journal of Polymer Science: Polymer Symposium, 66: 259-268 (1979).
Masuzawa, M., et al., “Experimental Study Related to the Hemostasis Action of GT XIII,” The Clinical Report, 20(2): 471-476 (Feb. 1986).
Matsumoto, K., et al., “A Gelatin Coated Collagen—Polyglycolic Acid Composite Membrane as a Dural Substitute,” American Society for Artificial Internal Organs Journal, 47: 641-645 (2001).
Maurer, P, et al., “Vicryl (Polyglactin 910) Mesh as a Dural Substitute,” Journal of Neurosurgery, 63:448-452 (1985).
Maxson, W.S., et al., “Efficacy of a modified oxidized cellulose fabric in the prevention of adhesion formation.” Gynecol. Obstet. Invest., 26: 160-165 (1988).
McClure, J., et al., “Massive Gastroduodenal Hemorrhage: Treatment with Powdered Gelfoam and Buffered Thrombin Solution,” Surgery, 32: 630-637 (1952).
McPherson, J., et al., “An Examination of the Biologic Response to Injectable, Glutaraldehyde Cross-linked Collagen Implants,” Journal of Biomedical Materials Research, 20: 93-107 (1986).
McPherson, J., et al., “Development and Biochemical Characterization of Injectable Collagen,” J. Dermatol. Surg. Oncol., 12(1): 13-20 (Jul. 7, 1988).
McPherson, J., et al., “The Effects of Heparin on the Physiochemical Properties of Reconstituted Collagen,” Collagen and Related Research, 1: 65-82 (1988).
McPherson, J., et al., “The Preparation and Physiochemical Characterization of an Injectable Form of Reconstituted, Glutaraldehyde Crosslinked, Bovine Corium Collagen,” Journal of Biomedical Materials Research, 20: 79-92 (1986).
Meddings, N., et al., “Collagen Vicryl—A New Dural Prosthesis,” Acta Neurochirurgica, 117: 53-58 (1992).
Mello, L., et al., “Duraplasty with Biosynthetic Cellulose: An Experimental Study,” Journal of Neurosurgery, 86: 143-150 (1997).
Miller, D., and Peppas, N., “Diffusional Effects During Albumin Adsorption on Highly Swollen Poly(vinyl Alcohol) Hydrogels,” Eur. Polym. J., 24(7): 611-615 (1988).
Miller, E.D., et al., “Dose-Dependent Cell Growth in Response to Concentration Modulated Patterns of FGF-2 Printed on Fibrin,” Biomaterials, 27: 2213-2221 (2006).
Millikan, L., “Treatment of Depressed Cutaneous Scars with Gelatin Matrix Implant: A Multicenter Study,” J. Am. Acad. Dermatol., 16: 1155-1162 (1987).
Min et al., “Molecular Weight Changes of Sodium Hyaluronate Powder and Solution by Heat treatment,” Matrix Biology Institute, Proceedings of Hyaluronan, Oct. 11-16, 2003.
Mitsuhashi, J., “Invertabrate Tissue Culture Methods,” Springer Lab Manual, p. 407 (2002).
Moak, E., “Hemostatic Agents: Adjuncts to Control Bleeding,” Today's O.R. Nurse, pp. 6-10 (1991).
Mueller, K., “Release and Delayed Release of Water-Soluble Drugs from Polymer Beads with Low Water Swelling,” Controlled-Release Technology—Pharmaceutical Applications, Ch. 11, ACS Symposium Series, 348: 139-157 (1986).
Muranyi, et al., “Development of gel-forming lyophilized formulation with recombinant human thrombin”, Drug Development and Industrial Pharmacy 41(9): (2015) 1566-1573. (Abstract Only).
Narotam, P., et al., “A Clinicopathological Study of Collagen Sponge as a Dural Graft in Neurosurgery,” Journal of Neurosurgery, 82: 406-412 (1995).
Narotam, P., et al., “Experimental Evaluation of Collagen Sponge as a Dural Graft,” British Journal of Neurosurgery, 7: 635-641 (1993).
Nimni, M., et al., “Chemically Modified Collagen: A Natural Biomaterial for Tissue Replacement,” Journal of Biomedical Materials Research, 21: 741-771 (1987).
Nimni, M., Ph.D., “The Cross-Linking and Structure Modification of the Collagen Matrix in the Design of Cardiovascular Prosthesis,” Journal of Cardiac Surgery, 3: 523-533 (1988).
Nogueira, L., et al., Comparison of gelatine matrix-thrombin sealants used during laparoscopic partial nephrectomy, BJU International, 102: 1670-1674 (2008).
Non-Final Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Oct. 2, 2014.
Non-Final Office Action for U.S. Appl. No. 14/383,461, titled: “Pressurized Container Containing Haemostatic Paste”, dated Jun. 15, 2017.
Non-Final Office Action for U.S. Appl. No. 14/516,728 dated Apr. 14, 2015 “Dry Haemostatic Composition”.
Non-Final Office Action for U.S. Appl. No. 14/516,728, titled: “Dry Haemostatic Composition” dated Nov. 25, 2014.
Non-Final Office Action for U.S. Appl. No. 14/980,254, titled: “Dry Haemostatic Composition”, dated May 8, 2017.
Notice of Allowability for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Jun. 12, 2017.
Notice of Allowance for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing” dated Sep. 23, 2016.
Notice of Allowance for U.S. Appl. No. 14/516,728, titled: “Dry Haemostatic Composition” dated Nov. 27, 2015.
Notice of Allowance for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated May 30, 2017.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/EP2015/080761, “Syringe for Retaining and Mixing First and Second Substances”, dated Feb. 19, 2016.
Novak, D., “Embolization Materials,” Interventional Radiology, pp. 295-313 (1990).
O'Neill, P., et al., “Use of Porcine Dermis as a Dural Substitute in 72 Patients,” Journal of Neurosurgery, 61: 351-354 (1984).
Office Action for U.S. Appl. No. 14/136,578, titled: “Device for Promotion of Hemostasis and/or Wound Healing”, dated Aug. 13, 2015.
Office Action for U.S. Appl. No. 14/895,674, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Feb. 6, 2017.
Ofner, C.M. and Bubnis, W.A., “Chemical and Swelling Evaluations of Amino Group Crosslinking in Gelatin and Modified Gelatin Matrices,” Pharma. Res., 13: 1821-1827 (1996).
Oyelese, Yinka, et al., “Postpartum Hemhorrage,” Obstetrics and Gynecology Clinics of North America 34.3, 421-441 (2007).
Oz, M.C., et al., “Controlled clinical trial of a novel hemostatic agent in cardiac surgery.”, Ann Thorac Surg, 69: 1376-1382 (2000).
Oz, M.C., et al., “Floseal-Matrix: New Generation Topical Hemostatic Sealant”, J. Card. Surg., 18: 486-493 (2003).
Palm, S., et al., “Dural Closure with Nonpenetrating Clips Prevents Meningoneural Adhesions: An Experimental Study in Dogs,” Neurosurgery, 45(4): 875-882 (1999).
Parizek, J., et al., “Detailed Evaluation of 2959 Allogeneic and Xenogeneic Dense Connective Tissue Grafts (Fascia Lata, Pericardium, and Dura Mater) Used in the Course of 20 Years for Duraplasty in Neurosurgery,” Acta Neurochirurgica, 139: 827-838 (1997).
Park, Y-K., et al., “Prevention of Arachnoiditis and Postoperative Tethering of the Spinal Cord with Gore-Tex Surgical Membrane: An Experimental Study with Rats,” Neurosurgery, 42(4): 813-824 (1998).
Peppas, N. and Barr-Howell, B., “Characterization of the Cross-Linked Structure of Hydrogels,” Ch. 2: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 27-56 (1986).
Peppas, N. and Brannon-Peppas, L, “Hydrogels at Critical Conditions. Part 1. Thermodynamics and Swelling Behavior,” Journal of Membrane Science, 48: 281-290 (1990).
Peppas, N. and Khare, A., “Preparation, Structure and diffusional Behavior of Hydrogels in Controlled Release,” Adv. Drug Delivery Reviews, 11: 1-35 (1993).
Peppas, N. and Korsmeyer, R, “Dynamically Swelling Hydrogels in Controlled Release Applications,” Ch. 6: Hydrogels in Medicine and Pharmacy, vol. III: Properties and Applications, N. Peppas ed., pp. 109-135 (1987).
Peppas, N. and Lustig, S., “Solute Diffusion in Hydrophilic Network Structures,” Ch. 3: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 57-83 (1986).
Peppas, N. and Mikos, A., “Preparation Methods and Structure of Hydrogels,” Ch. 1: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 1-25 (1986).
Peppas, N. and Moynihan, H, “Structure and Physical Properties of Poly(2-Hydroxyethyl Methacrylate) Hydrogels,” Ch. 2: Hydrogels in Medicine and Pharmacy, vol. II: Polymers, N. Peppas ed., pp. 49-64 (1987).
Peppas, N., “Hydrogels and Drug Delivery,” Current Opinion in Colloid & Interface Science, 2: 531-537 (1997).
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 1. Fundamentals, CRC Press, Boca Raton, FL, 180 pages (1986).
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 2. Polymers, CRC Press, Boca Raton, FL, 172 pages (1987).
Peppas, N., “Hydrogels in Medicine and Pharmacy,” Hydrogels in Medicine and Pharmacy, vol. 3. Properties and Applications, CRC Press, Boca Raton, FL, 196 pages (1987).
Peppas, N., “Hydrogels of Poly (Vinyl Alcohol) and its Copolymers,” Ch. 1: Hydrogels in Medicine and Pharmacy, vol. II: Polymers, N. Peppas ed., pp. 57 pgs (1987).
Peppas, N., ed., “Other Biomedical Applications of Hydrogels,” Ch. 9: Hydrogels in Medicine and Pharmacy, vol. III: Properties and Applications, pp. 177-186 (1987).
Pietrucha, K., “New Collagen Implant as Dural Substitute,” Biomaterials, 12: 320-323 (1991).
Pitt, C., et al., “Biodegradable Drug Delivery Systems Based on Aliphatic Polyesters: Application to Contraceptives and Narcotic Antagonists,” Controlled Release of Bioactive Materials, R. Baker, ed., (NY: Academic Press) pp. 19-43 (1980).
Porchet, F., et al., “Inhibition of Epidural Fibrosis with ADCON-L: Effect on Clinical Outcome One Year Following Reoperation for Recurrent Lumbar Radiculopathy,” Neurological Research, 21: 551-560 (1999).
Product leaflet for FloSeal ®Matrix Hemostatic Sealant dated Jul. 2001 (Jul. 2001).
Pschyrembel®—Klinisches Wörterbuch, 261st edition, de Gruyter (2007).
Purdy, P.D., et al., “Microfibrillar collagen model of canine cerebral infarction”; Strokes, 20(10): 1361-1367 (Oct. 1989).
Quintavalla, J., et al., “Fluorescently labeled mesenchymal stem cells (MSCs) maintain mutlilineage potential and can be detected following implantation into Particular cartilage defects.”, Biomaterials, 23: 109-119 (2002).
Raftery, A., “Absorbable haemostatic materials and intraperitoneal adhesion formation.”; Br. J. Surg. 67; 1980; pp. 57-58.
Ratner, B., “Hydrogel Surfaces,” Ch. 4: Hydrogels in Medicine and Pharmacy, vol. I: Fundamentals, N. Peppas ed., pp. 85-94 (1986).
Raul, J.S., et al., “Utilisation du Polyester Urethane (Neuropatch) Comme Substitut Dural,” Neurochirugie, 49: 83-89, English abstract only on p. 83 (2003).
Reddy, M., et al., “A Clinical Study of a Fibrinogen-Based Collagen Fleece for Dural repair in Neurosergery,” Acta Neurochirurgica, 144: 265-269 (2002).
Reese, A.C., “Role of fibronectin in wound healing”, Report date: Sep. 12, 1986; Annual rept. Oct. 1, 1985-Mar. 31, 1986, Final rept. Oct. 1, 1983-Mar. 31, 1986. Corporate Author: Medical Coli of Gerogia Augusta Research Institute. Brunt and Klausner, “Growth factors speed wound healing”, Nature Biotechnology, 6(1): 25-30 (1988).
Reijnen, M.M.P.J., et al., “Prevention of intra-abdominal abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model.” Arch Surg. 134: 997-1001 (1999).
Renkens, K., et al, “A Multicenter, Prospective, Randomized Trial Evaluating a New Hemostatic Agent for Spinal Surgery,” Spine, 26(15): 1645-1650 (2001).
Riley, S., et al. “Percutaneous Liver Biopsy with Plugging of Needle Track: A Safe Method for Use in Patients with Impaired Coagulation,” Lancet, p. 436 (1984).
Roda, A., et al., “Protein Microdeposition Using a Conventional Ink-Jet Printer,” BioTechniques, 28(3): 492-496 (2000).
Romanelli, M., et al., “Exudate Management Made Easy”, downloaded from http://www.woundsinternational.com, 6 pgs., (Jan. 29, 2010).
Rosenblatt, J., et al., “Effect of Electrostatic Forces on the Dynamic Rheological Properties of Injectable Collagen Biomaterials,” Biomaterials, 13: 878-886 (1982).
Rosenblatt, J., et al., “Injectable Collagen as a pHSensitive Hydrogel,” Biomaterials, 12: 985-995 (1984).
Ross, J., et al., “Association Between Peridural Scar and Recurrent Radicular Pain After Lumbar Discectomy: Magnetic Resonance Evaluation,” Neurosurgery, pp. 855-863 (1996).
Rossler, B., et al., “Collagen Microparticles: Preparation and Properties,” Journal of Microencapsulation, 12: 49-57 (1995).
Sakurabayashi, S., et al., “Clinical evaluation of new hemostatic agent for hemostasis from biopsy wounds in the liver.”; Gastroenterological Endoscopy 30:(10) 29 pgs. (Oct. 1988).
Sanfilippo, J.S., et al., “Comparison of avitene, topical thrombin and Gelfoam as sole hemostatic agent in tuboplasties.”, Fertility and Sterility, 33(3): 311-316 (1980).
San-Galli, F., et al., “Experimental Evaluation of a Collagen-Coated Vicryl Mesh as a Dural Substitute,” Neurosurgery, 30: 396-401 (1992).
Santomaso, A., et al., “Powder flowability and density rations: the impact of granules packing”, Chemical Engineering Science, 58: 2857-2874 (2003).
Schramm, V., et al., “Gelfoam Paste Injection for Vocal Cord Paralysis,” The Laryngoscope, 88: 1268-73 (1978).
Schreiber, M.A., et al., “Achieving Hemostasis with Topical Hemostats: Making Clinically and Economically Appropriate Decisions in the Surgical and Trauma Settings”, AORN Journal, 94(5): S1-S20 (2011).
Shaffrey, C.I., et al., “Neurosurgical Applications of Fibrin Glue: Augmentation of Dural Closure in 134 Patients,” Neurosurgery, 26: 207-210 (1990).
Shushan, A., et al., “Hyaluronic acid for preventing experimental postoperative intraperitoneal adhesions.”, Journal of Reproductive Medicine, 39(5): 398-402 (1994).
Shuxian, M. and Zhili, C., “Clinical Observation of the Treatment of Hemoptysis by Ultrasonic Atomizing Inhalation of Thrombin”, Chinese Journal of Critical Care Medicine, 16(2): 30 (1996).
Sidman, K., et al., “Biodegradable, Implantable Sustained Release Systems Based on Glutamic Acid Copolymers,” Journal of Membrane Science, 7: 227-291 (1979).
Sigma-Aldrich Datasheet for “Hank's Balanced Salts,” revised Apr. 2007.
Simamora, P., et al., “Controlled delivery of pilocarpine. 2. In-vivo evaluation of Gelfoam® device,” International Journal of Pharmaceutics, 170(2): 209-214 (1998).
Smith, A., “New and Nonofficial Remedies: Absorbable Gelatin Sponge—Gelfoam-Upjohn,” Council on Pharmacy and Chemistry, 135(14): p. 921 (1947).
Smith, K., et al., “Delayed Postoperative Tethering of the Cervical Spinal Cord,” Journal of Neurosurgery, 81: 196-201 (1994).
Solar Biologicals Inc., “Solar-cult sampling products: Pre-moistened cellulose sponge sampling systems”, available at www.solarbiologicals.com/samp-sys.htm (Jul. 25, 2002).
Soules , M.R., et al., “The prevention of postoperative pelvic adhesions: An animal study comparing barrier methods with Dextran 70.”, Am. J. Obstet. Gynecol., 143(7): 829-834 (1982).
Spence et al., “Cerebellar capillary hemangioblastoma: its histogenesis studied by organ culture and electron microscopy.”, Cancer, 35(2): 326-341 (Feb. 1975).
Spotnitz, W. D., et al., “Hemostatus, Sealants, and Adhesives: Components of the Surgical Toolbox,” Transfusion, 48(7):1502-1516 (2008).
Springorum, H., “Die Verwendung von Kollagenfolien Zur Uberbruckung von Defekten des Gleitgewebes bei Achillotenotomien and Achillessehnenrupturen,” Akt. Traumatol., 15: 120-121, English abstract only on p. 120 (1985).
Stief, T. W., “Kallikrein Activates Prothrombin,” Clinical and Applied Thrombosis/Hemostasis, 14.1:97-98 (2008).
Stricker, A., et al., “Die Verwendung von TissuFoil Membran bei der Sinusbodenaugmentation,” Ellipse, 17: 1-5 (2001). English abstract only on p. 1.
Stuart Transport medium information sheet [retrieved online on May 27, 2009].
Sugitachi, A., et al., “A Newly Devised Chemo-Embolic Agent, G.T. XIIIADM,” Gan. To. Kagaku Ryoho, 12: 1942-1943 (1985). English abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 2, 2001.
Sugitachi, A., et al., “Locoregional Therapy in Patients with Malignant Pleural Effusion—Two Different Kinds of ‘BAC Therapy’,” Gan. To. Kagaku Ryoho, 19: 1640-1643 (1992). English abstract retrieved from http://www.ncbi.nlm.nih.gov on Jan. 3, 2001.
Sugitachi, A., et al., “Preoperative Transcatheter Arterial Chemo—Embolization for Locally Advanced Breast Cancer: Application for New Thrombotic Materials.” Japanese Journal of Surgery, 13: 456-458 (1992).
Surgiflo® Essential Prescribing Information, Hemostatic Matrix (Made from Absorbable Gelatin Sponge, U.S.P.), 1 page (2005).
Surgiflo® haemostatic matrix FlexTip, MS0009, 84 pages (2007).
Surgiflo® product leaflet, “Surgiflo® Hemostatic Matrix Kit,” 5 pages (2012).
Surgiflo® product leaflet, “Surgiflo® Hemostatic Matrix,” 12 pages (2009).
Swann, D.A.,“ Studies on hyaluronic acid-I. The preparation and properties of rooster comb hyaluronic acid”, Biochemica et biophysica acta, 156: 17-30 (1968).
Taheri, Z., “The Use of Gelfoam Paste in Anterior Cervical Fusion,” Journal of Neurosurgery, 34: 438 (1971).
Tobin, M., et al., “Plugged Liver Biopsy in Patients with Impaired Coagulation,” Digestive Diseases and Science, 34: 13-15 (1989).
Tucker, H., “Absorbable Gelatin (Gelfoam) Sponge,” Springfield, Illinois, Charles T. Thomas, pp. 3-125 (1965).
Van den Bosch, E., et al., “Gelatin degradation at elevated temperature”, International Journal of Biological Macromolecules, 32: 129-138 (2003).
Vandelli, M.A., et al., “The effect of the crosslinking time period upon the drug release and the dynamic swelling of gelatin microspheres,” Pharmazie, 46: 866-869 (1991).
Vander-Salm, T.J., et al., Abstract of “Reduction of sternal infection by application of topical vancomycin.”, J. of Thoracic and Cardiovascular Surgery, 98(4): 618-622 (1989).
Verhoeven, A.G., et al., “XV. The use of microporous polymeric powders for controlled release drug delivery systems,” Controlled Drug Delivery. Ch. 15, International Symposium of the Association for Pharmaceutical Technology (APV), Bad Homburg, Nov. 12-14, 1984, pp. 226-237.
Vinas, F., et al., “Evaluation of Expanded Polytetrafluoroethylene (ePTFE) versus Polydioxanone (PDS) for the Repair of Dura Mater Defects,” Neurological Research, 21: 262-268 (1999).
Wachol-Drewek, Z., et al., “Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin.”, Biomaterials, 17: 1733-1738 (1996).
Wallace, D., “The Relative Contribution of Electrostatic Interactions to Stabilization of Collagen Fibrils,” Biopolymers, 29: 1015-1026 (1990).
Wallace, D., et al., “Injectable Cross-Linked Collagen with Improved Flow Properties,” Journal of Biomedical Materials Research, 23: 931-945 (1989).
Warren, W., et al., “Dural Repair Using Acellular Human Dermis: Experience with 200 Cases: Technique Assessment,” Neurosurgery, 46: 1391-1396 (2000).
Wassersug, J.D., M.D., “Use of Human Thrombin in Some Cases of Pulmonary Hemorrhage” Pulmonary Hemorrhage, vol. XVII, pp. 354-356 (Mar. 1950).
Weeks, R., “Microscopy of Soft Materials,” Chapter 1 in Experimental and Computational Techniques in Soft Condensed Matter Physics, Jeffrey Olafsen, Ed, 2010 (2010).
West et al., “Efficacy of adhesion barriers: Resorbable hydrogel, oxidized regenerated cellulose and hyaluronic acid.”, The Journal of Reproductive Medicine, 41(3) 149-154 (1996).
Wiesenthal, A.A., et al., Abstract of “New method for packing the external auditory canal, middle ear space, and mastoid cavities after otologic surgery”, The Journal of Otolaryngology; 28(5): 260-265 (1999).
Wilkinson, H., et al., “Gelfoam Paste in Experimental Laminectomy and Cranial Trephination,” Journal of Neurosurgery, 54: 664-667 (1981).
Written Opinion for International Application No. PCT/DK2003/000855, “Gelatine-Based Materials as Swabs”, dated Feb. 28, 2005.
Written Opinion of the International Preliminary Examining Authority for counterpart International Application No. PCT/DK2011/050082, “A Method for Promotion of Hemostasis and/or Wound Healing”, dated Mar. 23, 2012.
Written Opinion of the International Searching Authority (Corrected Version) for International Application No. PCT/DK2005/000063, “Haemostatic Sprays and Compositions”, dated Jul. 26, 2005.
Written Opinion of the International Searching Authority for International Application No. PCT/DK2005/000475, “Haemostatic Composition Comprising Hyaluronic Acid”, dated Oct. 24, 2005.
Written Opinion of the International Searching Authority for International Application No. PCT/DK2009/050048, “Device for Promotion of Hemostatis and/or Wound Healing”, completed Aug. 31, 2010.
Wu, Y. et al., Abstract of “Design and experimental study of a slow-release antibiotic membrane implant in surgery wound.”, Intern. Des Services de San. Des Forces Armees; 72(7-9): 194-196 (Sep. 1999).
Xing, Q., et al., “Increasing Mechanical Strength of Gelatin Hydrogels by Divalent Metal Ion Removal”, Sci. Rep., 4: 4706: DOI:10.1038/srep04706(2014).
Xu, T., et al., “Viability and electrophysiology of neural cell structures generated by the inkjet printing method”, Biomaterials, 27: 3580-3588 (2006).
Xu, T., et al., “Inkjet Printing of Viable Mammalian Cells,” Biomaterials, 26: 93-99 (2005).
Yaping, G., “Observation and Nursing of the Treatment of Hemoptysis of Pulmonary Tuberculosis by Ultrasonic Atomizing Inhalation of Thrombin”, Journal of Qilu Nursing, 10(2): 126 (Feb. 2004).
Youwen, W. et al., “Clinical Observation of the Therapeutic Efficacy of the Treatment of 15 Patients with Hemoptysis by Ultrasonic Atomizing Inhalation of Thrombin”, Chengdu Medical Journal, 30(5): 262 (Oct. 2004).
Yuki, N., et al., “Effects of Endoscopic Variceal Sclerotherapy Using GT XIII on Blood Coagulation Tests and the Renal Kallikrein-Kinin System,” Gastroentral. Japan, 25: 561-567 (1990). English abstract retrieved from http://www.ncbi.nlm.nih.gov [retrieved on Jan. 2, 2001].
Ziegelaar, B., et al., “The Characterisation of Human Respiratory Epithelial Cells Cultured on Resorbable Scaffords: First Steps Towards a Tissue Engineered Tracheal Replacement,” Biomaterials, 23: 1425-1438 (2002).
Ziegelaar, B., et al., “Tissue Engineering of a Tracheal Equivalent, Doctoral Thesis,” Munich, Germany, Ludwig Maximilians University, 2004, 25 pages (2004).
Zins, M., et al., “US-Guided Percutaneous Liver Biopsy with Plugging of the Needle Track: A Prospective Study in 72 High-Risk Patients,” Radiology, 184: 841-843 (1992).
Notice of Allowance for U.S. Appl. No. 14/895,674, titled: “Dry Haemostatic Composition”, dated Jan. 24, 2018.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/EP2016/065260, “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, dated Oct. 4, 2016.
International Preliminary Report on Patentability for International Application No. PCT/EP2016/065260, “Syringe for Mixing Two Components and for Retaining a Vacuum in a Storage Condition”, date of completion Dec. 6, 2017.
Notice of Allowance for U.S. Appl. No. 15/534,801, “Syringe for Retaining and Mixing First and Second Substances”, dated Jul. 25, 2019.
Notice of Allowance for U.S. Appl. No. 15/534,801, titled: “Syringe for Retaining and Mixing First and Second Substances”, dated Jan. 16, 2020.
Notice of Allowance for U.S. Appl. No. 15/639,237, titled: “Vacuum Expanded Dry Composition and Syringe for Retaining Same”, dated Nov. 27, 2019.
Office Action for U.S. Appl. No. 15/963,795, titled: “Dry Haemostatic Composition”, dated Feb. 20, 2020.
Related Publications (1)
Number Date Country
20180147355 A1 May 2018 US